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A B S T R A C T
Purpose
To develop recommendations about endocrine therapy for women with hormone receptor
(HR) –positive metastatic breast cancer (MBC).
Methods
The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic
review of evidence from 2008 through 2015 to create recommendations informed by that evidence.
Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with
chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline
puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC.
Recommendations
Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC.
Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination,
should be used as initial treatment. Patients whose tumors express any level of hormone receptors
should be offered hormone therapy. Treatment recommendations should be based on type of
adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole
criteria for determining tumor progression; use of additional biomarkers remains experimental.
Assessment of menopausal status is critical; ovarian suppression or ablation should be included in
premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred
ﬁrst-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As
second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may
be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be
administered with exemestane to postmenopausal women with MBC whose disease progresses
while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor
receptor 2–positive MBC, human epidermal growth factor receptor 2–targeted therapy plus an AI
can be effective for those who are not chemotherapy candidates.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
INTRODUCTION
This clinical practice guideline provides treat-
ment recommendations for womenwith hormone
receptor (HR) –positive metastatic breast cancer
(MBC) who are being considered for endocrine
therapy. Breast cancer is the most prevalent cancer
inwomen in the developed world and is the second
most common cause of cancer-related death for
women in the United States. It was estimated that
in 2015, approximately 231,840 women in the
United States would be diagnosed with the disease,
and almost 40,000 would die as a result of it.1
Long-term survival outcomes are related to disease
stage at presentation. Currently, a majority of
patients presenting with localized disease will ex-
perience long-term disease-free survival, whereas
those presenting with or who develop metastatic
disease have a 5-year relative survival of only 24%,1
and almost none are cured. HR-positive breast
cancer represents the most common subset in both
the early- and late-stage settings, with . 70% of
tumors expressing these receptors, and recurrent
disease can be observed many years after initial
early-stage diagnosis.2,3
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THE BOTTOM LINE
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical
Oncology Guideline
Guideline Questions
1. Is there an optimal (deﬁned throughout this guideline as treatments with demonstrated beneﬁts in both treatment-related
and quality-of-life outcomes) ﬁrst-line endocrine therapy regimen for hormone receptor (HR) –positive metastatic breast
cancer (MBC)?
1.1 For postmenopausal women: What are the optimal sequence and duration?
1.2 Should hormone therapy be administered in combination with other hormonal agents or chemotherapy?
1.3 For premenopausal women: What is the optimal timing of ovarian suppression or ablation? Should all patients have
their ovaries suppressed? What is the best partner hormonal agent in this setting?
1.4 Are there demonstrated differences between pre- and postmenopausal patients?
2. Is there an optimal second- or later-line endocrine therapy for HR-positive MBC?
2.1 Should other treatment or disease-free interval play a role in treatment selection?
2.2 Which hormone therapy should be offered?
2.3 What are the optimal timing, dose, and schedule of treatment?
3. How or should endocrine therapies be used in combination or sequence with:
3.1 Mammalian target of rapamycin inhibitors (everolimus)?
3.2 Cyclin-dependent kinase 4/6 inhibitors (palbociclib)?
4. Does estrogen or progesterone expression (high v low expression) affect hormone therapy considerations and modify
recommendations for hormone therapy—either the recommended agents or dosing details—among pre-, peri-, and
postmenopausal women?
5. How does adjuvant treatment affect recommendations for treatment in the metastatic or advanced setting?
6. In which patients or settings is hormone therapy recommended over chemotherapy?
6.1 Is there a role for combined cytotoxic and endocrine therapies?
6.2 What is the optimal duration of treatment with hormonal therapy?
7. Is there a role for additional biomarkers in the selection of treatment for patients with HR-positive disease?
7.1 What is the role of genomic proﬁling or intrinsic subtypes in this population?
8. How does human epidermal growth factor receptor 2 (HER2) positivity affect treatment of patients with HR-positive
MBC?
9. What are the future directions for treatment in this patient population?
Target Population
Women with HR-positive MBC.
Target Audience
Health care providers (including primary care physicians, specialists, nurses, social workers, and any other relevant member of
a comprehensive multidisciplinary cancer care team) and patients.
Methods
The ASCO Expert Panel was convened to conduct a systematic review of evidence from 2008 through 2015 to create recommendations
informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with
chemotherapy, targeted biologic therapy, and treatment of premenopausal women.
ASCO Key Guideline Recommendations for HR-Positive MBC
• Hormone therapy should be offered to patients whose tumors express any level of estrogen and/or progesterone receptors.
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
• Treatment recommendations should be offered on the basis of type of adjuvant treatment, disease-free interval, and extent of
disease at the time of recurrence. A speciﬁc hormonal agent may be used again if recurrence occurs . 12 months from last
treatment.
• Endocrine therapy should be recommended as initial treatment for patients with HR-positive MBC, except for patients
with immediately life-threatening disease or for those experiencing rapid visceral recurrence during adjuvant endocrine
therapy.
• Treatment should be administered until there is unequivocal evidence of disease progression as documented by imaging,
clinical examination, or disease-related symptoms.
• The use of combined endocrine therapy and chemotherapy is not recommended.
• Patients should be encouraged to consider enrolling in clinical trials, including those receiving treatment in the ﬁrst-line
setting.
First-Line Therapy
• Postmenopausal women with HR-positive MBC should be offered aromatase inhibitors (AIs) as part of ﬁrst-line endocrine
therapy.
• Combination hormone therapy with a nonsteroidal AI and fulvestrant 500 mg and with a loading schedule may be offered for
patients with MBC without prior exposure to adjuvant endocrine therapy.
• Premenopausal women with HR-positive MBC should be offered ovarian suppression or ablation and hormone therapy,
because contemporary hormonal agents have only been studied among postmenopausal women.
Second-Line Therapy
• Sequential hormone therapy should be offered to patients with endocrine-responsive disease, except in the case of rapid
progression with organ dysfunction; no speciﬁc order of agents is recommended.
• When fulvestrant is administered, it should be administered using the 500-mg dose and with a loading schedule (treatment
start, day 15, day 28, then once per month).
Targeted Therapy
• A nonsteroidal AI and palbociclib may be offered to postmenopausal womenwith treatment-naı¨veHR-positiveMBC, because
progression-free survival (PFS) but not overall survival (OS) was improved compared with letrozole alone.
• Exemestane and everolimus may be offered to postmenopausal womenwith HR-positive MBC who experienced during prior
treatment with nonsteroidal AIs with or without one line of prior chemotherapy, either before or after treatment with
fulvestrant, because PFS but not OS was improved compared with exemestane alone.
• Fulvestrant and palbociclib may be offered to patients who experienced progression during prior treatment with AIs with or
without one line of prior chemotherapy, because PFS was improved compared with fulvestrant alone. Treatment should be
limited to those without prior exposure to cyclin-dependent kinase 4/6 inhibitors.
• The addition of HER2-targeted therapy to ﬁrst-line AIs should be offered to patients with HR-positive, HER2-positive MBC
in whom chemotherapy is not immediately indicated.
• Genomic or expression proﬁling should not be used at this time to select treatment for HR-positive MBC.
Qualifying Statements
• Tumor markers or circulating tumor cells should not be used as the sole criteria for determining disease progression.
• Providers should recognize and acknowledge special issues faced by premenopausal women with MBC, including loss of
fertility.
• Treatment should take into account the biology of the tumor and the menopausal status of the patient, with careful attention
paid to ovarian production of estrogen.
• There is more toxicity associated with the combination of exemestane and everolimus compared with other single-agent
endocrine options.
• There is more toxicity associated with the combination of palbociclib and endocrine therapy compared with other single-
agent endocrine options.
(continued on following page)
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Options for endocrine therapy have expanded in the last two
decades, with the availability of new and effective agents. Many of
these treatments have now been incorporated into the early-stage
setting, with both extended duration and use of sequential
therapy. The forwardmovement of new drugs from the advanced- to
the early-stage setting has complicated choices for metastatic disease,
increasing the importance of guidelines that summarize available
evidence. In addition, a greater understanding of the biologic path-
ways that contribute to hormone resistance has led to approval
of targeted agents administered in combination with hormone
therapy, including trastuzumab, everolimus, and palbociclib, and
multiple studies are ongoing.4-7 Treatment of premenopausal
women is a particular challenge, with questions regarding timing
of ovarian suppression and optimal use of hormonal agents.
This guideline will address endocrine therapy for the treat-
ment of HR-positive MBC. For the purposes of this guideline,
postmenopausal is deﬁned as either nomenses for at least 12months
in the absence of chemotherapy, oophorectomy, or ovarian
suppression with gonadotropin-releasing hormone (GnRH)
agonists.
INITIAL TREATMENT: ENDOCRINE THERAPY OR CHEMOTHERAPY
One important question is whether ﬁrst-line therapy for
HR-positive MBC should be chemotherapy or endocrine therapy.
There are limited data to answer this question amid current
treatment options. Historical literature suggests that neither
survival nor quality of life (QoL) is improved by treating patients
with chemotherapy when hormone therapy has a reasonable
chance of providing disease control.8 Randomized trials con-
ducted in previous decades for patients with de novo metastatic
disease suggested equivalent long-term rates of tumor control and
survival with either approach. In addition, an analysis of hormone
therapy trials in the ﬁrst-line setting demonstrated similar duration of
disease control regardless of visceral organ involvement in the absence
of immediately life-threatening disease.9
A second question is whether there is beneﬁt in combining
chemotherapy and hormone therapy. Again, historical data suggest
that sequential single-modality treatment is equivalent or preferred
to combination therapy, although formal comparisons are weak
with respect to clinically important end points including symptom
control, progression-free survival (PFS), and overall survival (OS).10,11
For these reasons, the recommended initial course of treatment for
HR-positive MBC is endocrine therapy. The Expert Panel acknowl-
edges that there are situations in which chemotherapy is appropriate
as initial therapy for HR-positive MBC, including in patients
with immediately life-threatening disease, where the time to
treatment response may be critical and where there may be
a near-term advantage in chemotherapy. Chemotherapy-appropriate
situations may also include those where tumor biology (eg, extremely
low levels of estrogen receptor [ER]) makes endocrine treatment less
likely to be effective or in patients with HR-positive, human epidermal
growth factor receptor 2 (HER2) –positive breast cancer, for whom
combining chemotherapy and anti-HER2 treatments has a survival
advantage. Fortunately, rapidly progressive immediately life-
threatening disease is relatively uncommon among womenwithHR-
positive MBC. For ASCO guidance on the use of chemotherapy in
advanced breast cancer, please see the Clinical Practice Guideline on
chemotherapy and targeted therapy for women with HER2-negative
(or unknown) advanced breast cancer.11a
COMBINATIONS OF HORMONE THERAPY OR HORMONE
THERAPY WITH TARGETED AGENTS
Existing data suggest that combinations of hormone therapy
should be considered only in speciﬁc situations, although ongoing
THE BOTTOM LINE (CONTINUED)
• Palbociclib should be administered once per day for 21 days every 28 days; the primary toxicity is neutropenia. Blood counts
should be monitored every 14 days for the ﬁrst two 28-day cycles, then at the start of each subsequent cycle, with neutropenia
managed by dose delays and reductions. Although no data exist at present, any AI could be substituted depending on
individual tolerance. On the basis of the data from PALOMA-3, palbociclib can also be combined with fulvestrant in the
second-line setting or greater, including after one line of chemotherapy.
• Chemotherapy in combination with HER2-targeted therapy is indicated in de novo and visceral dominant disease, because
this treatment offers a survival beneﬁt compared with chemotherapy alone.
• There is no routine clinical role for genomic or expression proﬁling in the selection of treatment for HR-positive MBC.
Additional Resources
More information, including Data Supplements with additional evidence tables, a Methodology Supplement with information
about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at http://www.
asco.org/guidelines/advancedendocrinebreast and http://www.asco.org/guidelineswiki. Patient information is available at http://
www.cancer.net/.
ASCO believes that cancer clinical trials are vital to informmedical decisions and improve cancer care and that all patients should
have the opportunity to participate.
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trials are evaluating additional settings and drug doses. Discordant
results have been reported on combinations of the selective ER
downregulator fulvestrant and aromatase inhibitors (AIs) in the ﬁrst-
line setting; one randomized study showed improved PFS and OS,
favoring the combination over the AI alone, but another with a similar
design showed equivalent PFS and OS.12,13 Subset analysis suggested
that the survival beneﬁt was primarily observed in patients without
exposure to prior endocrine therapy. A phase II trial comparing
fulvestrant with anastrozole as ﬁrst-line therapy for hormone-na¨ıve
MBC demonstrated no improvement in the primary end point of
clinical beneﬁt, but subsequent follow-up suggested improved time to
progression (TTP) andOSwith use of fulvestrant; an ongoing phase III
trial is exploring this comparison (Data Supplement 8 provides details
on the FALCON [AGlobal Study to Compare the Effects of Fulvestrant
and Arimidex in a Subset of Patients With Breast Cancer] trial
[ClinicalTrials.gov identiﬁer NCT01602380]).14,15 Few studies have
demonstrated a survival beneﬁt for one treatment compared with
another in postmenopausal patients with HR-positive MBC; for that
reason, variation in sequencing or the use of combination
therapy can be offered. Hormone therapy administered in
combination with agents targeted to pathways implicated in
hormone resistance is under intense evaluation, with both
failures and recent successes. The mammalian target of rapa-
mycin (mTOR) inhibitor everolimus, administered in com-
bination with the steroidal AI exemestane in patients with
progressive disease or disease resistant to nonsteroidal AIs
(letrozole or anastrozole), demonstrated improved PFS compared
with exemestane alone but was associated with increased toxicity
and did not improve OS; these data led to US Food and Drug
Administration (FDA) approval of everolimus and exemestane.4,16
The addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor
palbociclib, administered as ﬁrst-line therapy in combination with
the nonsteroidal AI letrozole, in an open-label phase II trial also
signiﬁcantly improved PFS without improving OS.7 This combi-
nation was well tolerated, although the study was small.
Accelerated approval for palbociclib was granted early in 2015,
pending results from a phase III trial with a similar design (Data
Supplement 8 provides details on the PALOMA-2 [Palbociclib:
Ongoing Trials in the Management of Breast Cancer] trial). Pal-
bociclib was also studied as second-line therapy for HR-positive
MBC in combination with fulvestrant in a placebo-controlled
phase III trial. The addition of palbociclib signiﬁcantly im-
proved PFS, with a toxicity proﬁle similar to that shown in the
phase II trial; survival data are immature.17 Global QoL was
generally maintained in the palbociclib arm, but it deteriorated in
those receiving placebo. Therapy targeted to HER2 combined with
hormonal agents in patients with HR-positive, HER2-positive
MBC also resulted in improved PFS compared with hormonal
agents alone, without improved survival.5,6 Controversy exists
about how to use these novel drugs in clinical practice. Additional
agents targeting a number of pathways are in phase III trials as well
(Data Supplement 8).
TREATMENT OF PREMENOPAUSAL WOMEN
Premenopausal women have generally not been included in clinical
trials testing hormone therapy, particularly in the ﬁrst-line setting.
As in postmenopausal women, the choice of treatment in the
metastatic setting is dependent on treatment administered for
early-stage disease. Questions are ongoing regarding the use of
ovarian suppression in combination or in sequence with hor-
monal agents18,19 and the sequencing of tamoxifen and AIs. Ran-
domized trials have shown a survival advantage with the combination
of ovarian suppression and hormone therapy, and all contemporary
hormonal agents have been studied only in postmenopausal
women.14,15,20-26 Data from the early-stage setting may offer
additional insight.
BIOPSIES FOR METASTATIC DISEASE
The panel considers it mandatory for all patients to have ER and
HER2 status determined in their cancers. Often a biopsy is rec-
ommended to determine or conﬁrm whether a suspicious lesion
represents MBC; in this case, markers should be obtained.27 In
addition, the panel believes that in most settings, recurrent disease
should be biopsied whenever feasible for determination of tumor
ER and HER2 status, because these markers guide therapy for
metastatic disease. A number of studies have reported discordance
between marker status in early- and late-stage disease, which re-
sults in a change in management in up to 14% of patients.28
However, at present, there is a lack of clear evidence that a change
in markers in the metastatic lesion is predictive of response to
therapy.
Caution should be exercised in interpreting information
obtained from bone biopsies, because processing may alter
ER and/or HER2 testing results, or biopsies may contain few
tumor cells, and results may not be reliable.29 Although biop-
sies are recommended in the majority of patients to conﬁrm
diagnosis and evaluate markers, there may be some patients
for whom there is adequate information available from the
primary tumor. Given the increasing number of options for
the treatment of patients with MBC with hormone therapy
and the controversies outlined, a clinical practice guideline is
warranted.
CLINICAL PRACTICE GUIDELINES
Practice guidelines are systematically developed statements that
assist practitioners and patients in making decisions about care.
Attributes of good guidelines include validity, reliability, re-
producibility, clinical applicability, ﬂexibility, clarity, a multidisci-
plinary process, review of evidence, and documentation.
Guidelines may be useful in producing better care and decreasing
cost. Speciﬁcally, use of clinical guidelines may provide im-
provements in outcomes, improvements in medical practice,
a means for minimizing inappropriate practice variation, decision
support tools for practitioners, points of reference for medical ori-
entation and education, criteria for self-evaluation, indicators and
criteria for external quality review, assistance with re-
imbursement and coverage decisions, criteria for use in cre-
dentialing decisions, and identiﬁcation of areas where future
research is needed.
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Panel Composition
To address the clinical question, an Expert Panel was convened
with multidisciplinary representation in medical oncology, radiation
oncology, psycho-oncology, patient advocacy, and guideline method-
ology. The Expert Panel was led by two co-chairs who had the primary
responsibility for the development and timely completion of the
guideline. The Expert Panel members are listed in Data Supplement 6.
Guideline Development Process
The Expert Panel members, who met face to face and via
teleconference and corresponded through e-mail, were asked to
contribute to the development of the guideline, provide critical
review, interpret evidence, and ﬁnalize the guideline recommen-
dations based on consideration of the evidence. Members of the
Expert Panel were responsible for drafting the penultimate version
of the guideline, which was then circulated for external review and
submitted to Journal of Clinical Oncology for editorial review and
publication. All ASCO guidelines are reviewed and approved by the
ASCO Clinical Practice Guideline Committee before publication.
Guideline Disclaimer
The clinical practice guidelines and other guidance published
herein are provided by the American Society of Clinical Oncology,
Inc. (“ASCO”) to assist providers in clinical decision making. The
information therein should not be relied upon as being complete or
accurate, nor should it be considered as inclusive of all proper
treatments or methods of care or as a statement of the standard of
care. With the rapid development of scientiﬁc knowledge, new
evidence may emerge between the time information is developed
and when it is published or read. The information is not continually
updated and may not reﬂect the most recent evidence. The in-
formation addresses only the topics speciﬁcally identiﬁed therein
and is not applicable to other interventions, diseases, or stages of
diseases. This information does notmandate any particular course of
medical care. Further, the information is not intended to substitute
for the independent professional judgment of the treating provider,
as the information does not account for individual variation among
patients. Recommendations reﬂect high, moderate or low conﬁ-
dence that the recommendation reﬂects the net effect of a given
course of action. The use of words like “must,” “must not,” “should,”
and “should not” indicate that a course of action is recommended or
not recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of action in
individual cases. In all cases, the selected course of action should be
considered by the treating provider in the context of treating the
individual patient. Use of the information is voluntary. ASCO
provides this information on an “as is” basis, andmakes nowarranty,
express or implied, regarding the information. ASCO speciﬁcally
disclaims any warranties of merchantability or ﬁtness for a particular
use or purpose. ASCO assumes no responsibility for any injury or
damage to persons or property arising out of or related to any use of
this information or for any errors or omissions.
Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with ASCO’s
Conﬂict of Interest Policy Implementation for Clinical Practice
Guidelines (“Policy,” found at http://www.asco.org/rwc). All mem-
bers of the panel completed ASCO’s disclosure form, which
requires disclosure of ﬁnancial and other interests, including re-
lationships with commercial entities that are reasonably likely to
experience direct regulatory or commercial impact as a result of
promulgation of the guideline. Categories for disclosure include
employment; leadership; stock or other ownership; honoraria; con-
sulting or advisory role; speakers bureau; research funding; patents,
royalties, other intellectual property; expert testimony; travel, ac-
commodations, expenses; and other relationships. In accordance with
the Policy, the majority of the members of the panel did not disclose
any relationships constituting a conﬂict under the Policy.
METHODS
Systematic Literature Review
ASCO guidelines are based on systematic reviews. A protocol for each
guideline deﬁnes the parameters for a targeted literature search, including
relevant study designs, literature sources, types of reports, and prespeciﬁed
study selection criteria for literature identiﬁed.
Literature Search Strategy
The MEDLINE (OVID: 2008 through week 4 of April 2014) and
Cochrane Library databases (http://www.cochranelibrary.com; to Issue 3
of March 2013) were searched for evidence reporting on outcomes of
interest. Additionally, the San Antonio Breast Cancer Symposium (2011 to
2014) and ASCO abstracts (2012 to 2014) were searched for reports on
systematic reviews (with or without meta-analyses) and randomized
controlled trials (phase II or III) using the keywords “advanced” and
“metastatic” and were reviewed for terms relating to HR status, publication
type, and study design. Reference lists from seminal papers and recent
review articles were scanned for additional citations, and known updates of
included evidence were obtained as available. A targeted literature search
update was performed in June 2015 to obtain the most recent evidence.
The literature search strategy used in the MEDLINE database is available in
Data Supplement 1.
Study Selection Criteria
Articles were selected for inclusion in the systematic review of the
evidence if they were fully published or abstract reports of systematic
reviews (with or without meta-analyses) or randomized controlled trials
(phase II or III), published in English, that reported on any of the following
interventions: endocrine therapies, including selective ER modulators
(tamoxifen or toremifene), ER downregulators (fulvestrant), progestins
(megestrol acetate or medroxyprogesterone), luteinizing hormone–releasing
hormone analogs (goserelin, leuprorelin, or buserelin), nonsteroidal
third-generation AIs (anastrozole or letrozole), and steroidal third-generation
AIs (exemestane); mTOR inhibitors (everolimus or temsirolimus); CDK 4/6
inhibitors (palbociclib); estrogens; and chemotherapy.
Selected articles made any of the following comparisons: single-
agent versus single-agent hormone therapies, single-agent versus com-
bination endocrine therapies, endocrine therapy with or without HER2-
targeted therapies, endocrine therapy with or without mTOR inhibitors,
endocrine therapy with or without CDK 4/6 inhibitors, and endocrine
therapy with or without novel agents. Articles were also required to
report on primary outcomes of interest (including OS, PFS or TTP, or
clinical beneﬁt rate [CBR; stable disease plus response rate]) or sec-
ondary outcomes of interest (including time to initiation of chemo-
therapy, toxicity, or QoL as measured by a validated, reliable instrument
[eg, Short Form Health Survey 36]). Articles were excluded from the
systematic review if they were noncomparative studies.
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Data Extraction
Literature search results were reviewed and deemed appropriate for
full-text review by an ASCO staff member in consultation with the panel
co-chairs. Data were extracted by one ASCO staff member and sub-
sequently checked for accuracy through an audit of the data by another
ASCO staff member. Disagreements were resolved through discussion and
consultation with the co-chairs if necessary.
Revision Dates
The co-chairs determine the need for guideline updates or revisions
on the basis of periodic review and consideration of the literature. If new
and compelling data are identiﬁed, the Expert Panel or an update com-
mittee is reconvened to discuss revisions to the document.
RESULTS
A total of 36 articles, including seven systematic reviews
with meta-analyses8,30-35 (Table 1) and 29 individual trial
reports,6,7,12,13,15,17,20,22-26,36-52 met the inclusion criteria. Four
of these trials15,21,42,50 had their ﬁndings published in multiple
reports,4,5,14,21,50 which are indicated in the tables and text where
appropriate. The 29 primary studies6,7,12,13,15,17,20,22-26,36-52 in-
cluded nine trials15,20,22-26,36,37 that compared single-agent
versus single-agent hormone therapies, three12,13,38 compared
single-agent versus combination endocrine therapies, one39 com-
pared endocrine therapy with or without epidermal growth factor
receptor (EGFR) –targeted therapies, four6,40-42 compared endocrine
therapy with or without HER2-targeted therapies, three43-45 com-
pared endocrine therapy with or without mTOR inhibitors, and two
compared endocrine therapy with or without CDK 4/6 inhibition7,17
and, for novel agents; one trial46 compared endocrine therapy with
or without rearranged during transfection (RET) vascular en-
dothelial growth factor receptors (VEGFRs) and an EGFR tyrosine
kinase inhibitor (TKI); one47 compared endocrine therapy with or
without an insulin-like growth factor receptor (IGFR) antibody;
two48,49 compared endocrine therapy with or without a VEGF
antibody, one50 compared endocrine therapy with or without
a histone deacetylase (HDAC) inhibitor, and two51,52 compared
endocrine therapy with a pan–phosphatidylinositol 3-kinase
(PI3K) inhibitor. All trial data are listed in Tables 2–5, and de-
scriptions of the regimens used in each trial are provided in Data
Supplement 7. The outcomes for each comparison will be discussed
in their own section.
Systematic Reviews With or Without Meta-Analyses
A total of seven systematic reviews with meta-analyses were
obtained.8,30-35 One8 compared single-agent endocrine therapy
against single-agent chemotherapy, three compared single-agent
versus single-agent hormone therapies,30-32 two compared
single-agent versus combination endocrine therapies,33,34 and
one compared endocrine therapy with or without mTOR
inhibitors.35
Five of these systematic reviews detected signiﬁcant differ-
ences between treatments. Wilcken et al,8 in a comparison of
single-agent endocrine therapy against single-agent chemotherapy,
found a signiﬁcant beneﬁt in response rates associated with
chemotherapy. Chi et al,30 in a comparison between toremifene
and tamoxifen, detected no differences between the two in efﬁcacy,
although toremifene was associated with signiﬁcantly greater
vaginal bleeding and lower serum triglycerides. Cope et al,31 in
a comparison among fulvestrant at two different doses, anastrozole,
megestrol, exemestane, and letrozole at two doses found fulvestrant
at 500 mg superior to fulvestrant at 250 mg, megestrol, and anas-
trozole for PFS. Xu et al,32 comparing AIs with tamoxifen, found AIs
superior for both response and CBR. Finally, Bachelot et al,35 in
a comparison between exemestane plus themTOR inhibitor everolimus
with everolimus plus tamoxifen or fulvestrant, found exemestane plus
everolimus superior to fulvestrant 250 mg and fulvestrant 500 mg for
both PFS and TTP. Details are listed in Table 1.
Study Characteristics
Single-agent versus single-agent hormone therapies. A total of
nine trials15,20-26,37 were obtained that compared single-agent
versus alternate single-agent hormone therapies. Four15,22,23,37
of these reported on ﬁrst-line treatment, and ﬁve20,21,24-26 re-
ported on second-line treatment. These nine trials included a total
of 3,661 patients, ranging from a low of 10323 to a high of 736.36
Median age ranged from a low of 53.4 years26 to a high of 72.6
years.23 All nine trials reported that only postmenopausal patients
were included, and three20,22,37 reported that HR-negative patients
were included, although the number of HR-positive patients were the
majority (94.8%,22 94.2%,37 and 98.3%,20 respectively). In the three
trials22,24,25 that reported on HER2 status, a majority of patients
were HER2-negative. Seven trials20,22-26,37 reported on patients
who had received previous chemotherapy, and four20,21,24,37
reported on patients who had received previous endocrine
therapy. Details are listed in Table 2.
Single-agent versus combination endocrine therapies. Three
trials12,13,38 were obtained that compared single-agent versus
combination endocrine therapies; two12,13 of these were in the
ﬁrst-line setting. These three trials included a total of 1,931 pa-
tients, ranging from a low of 51413 to a high of 723.38 The median
age ranged from a low of 63 years13 to a high of 66 years.38 Two
trials12,38 reported 100% of patients being postmenopausal, whereas
the third trial did not report menopausal status. Although the
number of HR-positive patients included in these trials
approached 100%, two13,38 reported including small numbers of
HR-negative patients (0.9%38 and 2.3%13). Two12,38 of the trials
reported on HER2 status, with Johnston et al38 reporting 93% of
patients being HER2 negative or unknown and Mehta et al12
reporting approximately 90% of patients being HER2 negative.
Both Mehta et al12 and Bergh et al13 reported the number of
patients who had received prior adjuvant chemotherapy and/or
endocrine therapy. Details are listed in Table 2.
Endocrine therapy with or without HER2-targeted therapies. Four
trials6,40-42 were found that compared endocrine therapy with or
without HER2-targeted therapies, all in the ﬁrst-line setting. These
four trials included a total of 1,133 patients, ranging from a low of
5741 to a high of 359.5 Themedian age ranged from a low of 54 years6
to a high of 61.5 years.41 All of these trials included only post-
menopausal patients. Although the proportion of HR-positive pa-
tients included in these ﬁve trials approached 100%, three trials
reported including small numbers of HR-negative patients.40-42 Two
trials5,6 did not report on HER2 status. Three trials6,40,42 reported
patients who had received prior chemotherapy, and four6,40-42
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included patients who had received prior endocrine therapy. Details
are listed in Table 2.
Endocrine therapy with or without mTOR inhibitors. Three
trials43,44,50 were found that compared endocrine therapy with or
without mTOR inhibitors, two43,44 in ﬁrst-line treatment and
one45 in the second-line setting. These three trials included a total
of 1,945 patients, ranging from a low of 11143 to a high of 1,110.44
The median age ranged from a low of 61 years45 to a high of 66
years.43 All of the patients included in these three trials were
postmenopausal and HR-positive, except those in the trial reported
by Wolff et al,44 which included a small number of HR-negative
patients. The trial by Piccart et al4,45,50 included 100%HER2-negative
patients, and the trial by Bachelot et al43 included 93% (tamoxifen
arm) and 98% (tamoxifen plus everolimus arm) HER2-negative
patients. One trial44 included . 50% HER2-positive patients.
Two43,44 included patients who had received previous chemotherapy.
All three trials included patients that had received prior endocrine
therapy. Details are listed in Table 2.
Endocrine therapy with or without a CDK 4/6 TKI. Two
trials7,17 were found comparing endocrine therapy with or without
Table 1. Main Findings From Systematic Review (all included meta-analyses)
Study Evidence Base Main Findings
Endocrine v chemotherapy
Wilcken8 Six trials including 692 patients with MBC (for OS comparison) No signiﬁcant difference in OS was detected (hazard
ratio, 0.94; 95% CI, 0.79 to 1.12; P 5 .5), with
nonsigniﬁcant heterogeneity detected
Compared single-agent endocrine treatment with single-agent
chemotherapy
Signiﬁcant beneﬁt in response rates (eight trials involving
817 women) for chemotherapy over endocrine therapy
was detected (RR, 1.25; 95% CI, 1.01 to 1.54; P5 .04)
Authors conclude that standard ﬁrst-line treatment for
patients with MBC should be endocrine therapy rather
than chemotherapy, except in presence of rapidly
progressing disease
Single-agent v single-agent
hormone therapies
Chi30 23 trials including 7,242 patients (patients with advanced breast
cancer were subset of total population)
Toremifene was associated with more vaginal bleeding
(OR, 0.45; 95% CI, 0.26 to 0.80; P < .05) and greater
decrease in serum triglyceride levels (SMD, 21.15;
95% CI, 21.90 to 20.39; P < .05) than tamoxifen
Compared toremifene and tamoxifen Evidence suggests toremifene could be an alternative to
tamoxifen for patients with advanced breast cancer
Cope31 11 RCTs including 5,808 postmenopausal women with
advanced breast cancer after endocrine therapy failure
Fulvestrant 500 mg was superior to fulvestrant 250 mg,
megestrolacetate, and anastrozole for PFS (P < .05)
Compared fulvestrant 500 mg, fulvestrant 250 mg, fulvestrant
250 mg loading dose, anastrozole 1 mg, megestrol acetate,
letrozole 2.5 mg, letrozole 0.5 mg, and exemestane
Xu32 Six RCTs including 2,560 postmenopausal patients with
HR-positive advanced breast cancer
AIs were superior to tamoxifen alone for response (ORR;
OR, 1.56; 95% CI, 1.17 to 2.07; P < .05) and CBR (OR,
1.70; 95% CI, 1.24 to 2.33; P < .05)
Compared AIs v tamoxifen
Single-agent v combination
endocrine therapies
Tan33 Two RCTs including patients with HR-positive advanced breast
cancer (total patients, NR)
None of the comparisons for PFS, OS, or response
showed statistically signiﬁcant difference
Compared fulvestrant1 AI v AI alone (both studied anastrozole
in combination with fulvestrant)
Valachis34 Four RCTs including 2,125 patients with HR-positive advanced
breast cancer
No difference detected between fulvestrant 1 AIs and
tamoxifen for OS, TTP, CBR, or ORR
Compared fulvestrant 1 AIs v tamoxifen Hormonal agents other than fulvestrant were associated
with great likelihood of joint disorders (P < .05)
Endocrine therapy6mTOR
inhibitors
Bachelot35 Six RCTs (total patients, NR) Everolimus 1 exemestane was superior to fulvestrant
250mg and fulvestrant 500mg for PFS and TTP (hazard
ratio, 0.47; 95% Cl, 0.38 to 0.58; P < .05 and hazard
ratio, 0.59; 95% Cl, 0.45 to 0.77; P < .05, respectively)
All patients had HR-positive, HER2-negative advanced breast
cancer
Analysis suggests that everolimus 1 exemestane is
superior to fulvestrant 250 mg and 500 mg for PFS and
TTP in patients with HR-positive, HER2-negative breast
cancer with disease progression after endocrine
therapy; however, there are no RCTs currently
available providing direct comparison
Included studies identiﬁed by systematic literature review
(sources: Cochrane Library, National Horizon Scanning
Centre, and NICE Web sites)
Comparisonswere: everolimus1 exemestane or everolimus1
tamoxifen v fulvestrant
Abbreviations: AI, aromatase inhibitor; CBR, clinical beneﬁt rate; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast
cancer; mTOR, mammalian target of rapamycin; NICE, National Institute for Health and Care Excellence; NR, not reported; ORR, overall response rate; OS, overall
survival; PFS, progression-free survival; RCT, randomized controlled trial; RR, response rate; TTP, time to progression.
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a CDK 4/6 TKI. One phase II trial7 in the ﬁrst-line setting included
165 postmenopausal patients, and the second phase III trial17 in the
second-line or greater setting included 521 postmenopausal pa-
tients, all with HR-positive disease. Details are listed in Table 2.
Endocrine Therapy With or Without Novel Agents
Endocrine therapy with or without an RET, VEGFR, and EGFR
TKI. One phase II trial46 in the ﬁrst-line setting was found that
compared endocrine therapy with or without a RET, VEGFR, and
EGFR TKI. This trial included 129 patients with a median age of
59 years. Some patients had received previous chemotherapy
(18%) or endocrine therapy (73%). Details are listed in Table 2.
Endocrine therapy with or without an IGFR antibody. One phase
II trial47 in the second-line setting was obtained that compared en-
docrine therapy with or without an IGFR antibody. This trial included
156 patients with amedian age of 61.5 years. This trial included a small
number of HR-negative patients, and a majority were HER2 negative
as well. Some patients had received previous chemotherapy (endo-
crine therapy arm, 64%; endocrine therapy plus IGFR arm, 67%) or
endocrine therapy (100%). Details are listed in Table 2.
Endocrine therapy with or without a VEGF antibody. Two
phase III trials48,49 in the ﬁrst-line setting were found that compared
endocrine therapy with or without a VEGF antibody. One trial
included 334 patients, and the second trial included 343 patients.
All included patients were postmenopausal, and a majority or all
had HR-positive disease. Details are provided in Table 2.
Endocrine therapy with or without an HDAC TKI. One phase
II trial50 in the second-line setting was found comparing en-
docrine therapy with or without an HDAC TKI. This trial in-
cluded 130 patients with a median age of 62.5 years. All included
patients were postmenopausal, with only a small number of HR-
negative patients included. Some patients had received previous
chemotherapy (endocrine therapy arm, 42%; endocrine therapy plus
HDAC TKI arm, 34%) or endocrine therapy (endocrine therapy arm,
86%; endocrine therapy plus HDAC TKI arm, 84%). Details are listed
in Table 2.
Endocrine therapy plus a pan-PI3K inhibitor. Two trials51,52—one
phase II51 and one phase III,52 both conducted in the second-line
setting—were found comparing endocrine therapy plus either a pan-
PI3K inhibitor or placebo. These two trials included a total of 1,147
patients, ranging from a low of 16851 to a high of 1,147.52 Median age
was 61 years in both trials. All patients included in the trials were
postmenopausal, all wereHRpositive, approximately 25%of all patients
in both trials had received prior chemotherapy forMBC, and all patients
had received prior endocrine therapy. Details are listed in Table 2.
Study Quality
As seen in the Study Quality Assessment Table in the
Methodology Supplement (online only), study quality was formally
assessed for the 29 trials identiﬁed. Design aspects related to individual
study quality were assessed by one reviewer and independently audited
by another, with factors such as blinding, allocation concealment
(blinding to treatment arm), placebo control, intention to treat,
funding sources, and so on considered. The overall risk of bias
was assessed as either low to intermediate or intermediate for the
included trials. Refer to the Methodology Supplement for deﬁ-
nitions of ratings for overall potential risk of bias.
Outcomes
Data on key outcomes of interest are listed in Table 3, separated
according to the comparison being made. Because all outcomes are
summarized in detail in Table 3, only trials that detected a signiﬁcant
difference for any of the outcomes of interest will be described here,
separated by comparison.
Single-agent versus single-agent hormone therapies. In a phase
II ﬁrst-line trial in which 205 patients were randomly assigned to
fulvestrant or anastrozole, Robertson et al15 detected a TTP beneﬁt
(23.4 v 13.1 months; P , .05) in favor of fulvestrant. The primary
outcome of this trial was CBR, which was similar between the two
arms (72.5% v 67%; P5 .386). OS was not deﬁned as an end point
in the original protocol, but it was assessed by a protocol amendment;
17% of patients were lost to follow-up. Median OS was 54.1
versus 48.4 months (P 5 .041) in this exploratory analysis. In
a phase III second-line trial in which 736 patients were randomly
assigned to fulvestrant 250 mg or fulvestrant 500 mg, Di Leo
et al21 detected beneﬁts in OS (26.4 v 22.3 months; P , .05) and
PFS (6.5 v 5.5 months; P , .05) in favor of the higher-dose
treatment.
Single-agent versus combination endocrine therapies. In a phase
III ﬁrst-line trial in which 694 patients were randomly assigned to
anastrozole alone or the combination of fulvestrant 250 mg plus
anastrozole, Mehta et al12 reported improved PFS (15 v 13.5 months;
P , .05) and OS (47.7 v 41.3 months; P , .05) in favor of the
combination treatment. In a second phase III ﬁrst-line trial, 514
patients were randomly assigned to anastrozole alone or the com-
bination of fulvestrant 250 mg plus anastrole. Bergh et al13 reported
no difference in either TTP (10.2 v 10.8 months; P 5 .91) or OS
(38.2 v 37.8 months; P5 1.00). There were demographic differences
between the patients enrolled in the two trials, suggesting that the
beneﬁt from combination therapy might have occurred primarily
in patients with de novo, untreated metastatic disease.
Endocrine therapy with or without HER2-targeted therapies. In
a phase III ﬁrst-line trial in which 219 patients were randomly
assigned to letrozole alone or letrozole with lapatinib, Schwartzberg
et al42 detected beneﬁts in PFS (8.2 v 3 months; P , .05) and CBR
(48% v 29%; P , .05) in favor of the combination treatment. In
another phase III ﬁrst-line trial in which 207 patients were randomly
assigned to anastrozole alone or anastrozole with trastuzumab,
Kaufman et al6 detected beneﬁts in PFS (4.8 v 2.4 months; P , .05)
and CBR (42.7% v 27.9%; P , .05) in favor of the combination
treatment. Finally, in a third phase III trial in which 295 patients
previously treated with an AI were randomly assigned to fulves-
trant with or without lapatinib regardless of HER2 status,
Burstein et al40 reported no beneﬁt in either PFS or OS. In the
HER2-positive subset (54 patients [18%]), a nonsigniﬁcant im-
provement in PFS (5.9 v 3.3 months; P 5 .53) was observed.
Endocrine therapy with or without mTOR inhibitors. In a phase
II open-label trial in which 111 patients previously treated with
letrozole or anastrozole were randomly assigned to tamoxifen or
tamoxifen with everolimus, Bachelot et al43 detected beneﬁts in
CBR (61% v 42%; P , .05) in favor of tamoxifen with everolimus.
An exploratory analysis suggested beneﬁt in both OS (32.9 v
median not yet reached; P , .05) and TTP (8.6 v 4.5 months;
P,.05) with the addition of everolimus to tamoxifen. In an update
of a phase III second-line trial in which 724 patients were randomly
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assigned to exemestane with everolimus or exemestance with
placebo at a ratio of two to one, Piccart et al45 reported beneﬁts in
PFS (7.4 v 3.2 months; P, .05) and CBR (50.5% v 25.5%; P, .05)
in favor of exemestane with everolimus. There was no statistically
signiﬁcant improvement in OS (31 v 26.6 months; P 5 .14).45
Endocrine therapy with or without a CDK 4/6 TKI. In a phase
II ﬁrst-line trial in which 165 patients were randomly assigned to
letrozole with palbociclib or letrozole alone, Finn et al7 detected
a median PFS beneﬁt (20.2 v 10.2 months; P , .001) in favor of
the combination arm. CBR and ORR were also improved in patients
receiving palbociclib. There was no difference in OS (37.5 v
33.3 months; P 5 .42). In a phase III trial in the second-line setting
or greater in which 521 patients were randomly assigned at a ratio of
two to one to fulvestrant with palbociclib or placebo, Turner et al17
reported signiﬁcant improvements in PFS (9.2 v 3.8 months;
P, .001) and CBR (34% v 19%; P, .001) in favor of the palbociclib
arm. At the time of this report, OS data were immature.
Endocrine therapy with or without an IGFR antibody. In
a phase II second-line trial in which 156 patients were randomly
assigned to ganitumab plus either fulvestrant or exemestane com-
pared with placebo plus either fulvestrant or exemestane, Robertson
et al47 detected a decrease in OS with ganitumab-based therapy
(HR 5 1.78; 80% CI, 1.27 to 2.50; P 5 .025).
Endocrine therapy with or without an HDAC TKI. In a phase II
second-line trial in which 130 patients were randomly assigned to
exemestane with entinostat or exemestane alone (plus placebo),
Yardley et al50 detected a median survival beneﬁt (28.1 v 19.8 months;
P, .05) in favor of the combination arm, although no difference was
detected for either PFS or CBR.
Endocrine therapy plus a pan-PI3K inhibitor. In a phase III
second-line trial in which 1,147 patients were randomly assigned to
fulvestrant with either placebo or buparlisib, Baselga et al52 re-
ported a modest beneﬁt in PFS (5 v 6.9 months; P, .001) in favor
of fulvestrant with buparlisib.
QoL
Data on QoL are listed in Table 4 for the four trials17,20,21,50
that reported QoL outcomes. In general, too few clinical trials in
this area incorporate appropriate patient-reported outcomes
(PROs) using suitable measures. Many use PRO or QoL measures
more suited for assessment in early breast cancer. Many of the
data are collected from subgroups of patients and incompletely
reported. The analyses used in studies that have incorporated
QoL as an outcome are often rather unsophisticated, reporting
mean values between groups rather than responder analyses, and
none seem to have considered clinically meaningful differences.
Consequently, the patient-perceived impact on QoL is not well
known. Evaluation of toxicities with the Common Terminology
Criteria for Adverse Events does not provide sufﬁcient insight
into the risk-versus-beneﬁt experience for the patient. It is
recommended that PRO measures be used (eg, PRO version of
Common Terminology Criteria for Adverse Events or Functional
Assessment of Cancer Therapy), along with relevant treatment-related
symptom subscales (eg, subscales for biologic modiﬁers, TKIs, and
endocrine symptoms). A listing of suitable measures can be found at
http://www.facit.org. It is important that PROs be included in ther-
apeutic clinical trials to understand the impact of treatment on QoL.
Adverse Events
Data on several key adverse events are listed in Table 5. Be-
cause all outcomes are summarized in detail in Table 5, only trials
that detected a signiﬁcant difference for any of the outcomes of interest
will be described here, separated by comparison. Distinctive adverse
effects of hormone therapy combined with targeted agents are noted
here. Clinicians and patients should consider toxicity proﬁles when
deciding on therapeutic options.
Single-agent versus combination endocrine therapies. In a phase
III ﬁrst-line trial in which 311 patients were randomly assigned to
anastrozole alone or fulvestrant with anastrozole, Bergh et al13
noted signiﬁcantly more hot ﬂashes associated with the combi-
nation arm (24.6% v 13.8%; P , .05).
Endocrine therapy with or without HER2-targeted therapies. In
a phase III trial in which 291 patients previously treated with an AIwere
randomly assigned to fulvestrantwith lapatinib or fulvestrant alone (with
placebo), Burstein et al40 reported signiﬁcantly higher grade 3 adverse
effects associated with the combination arm (19% v 5%; P, .05), and
a higher number of patients had to stop treatment early because of
adverse effects in the combination arm as well (12% v 2%; P , .05).
Endocrine therapy with or without mTOR inhibitors. Baselga
et al4,45,56 reported signiﬁcantly higher grade 3 stomatitis (8% v, 1%),
fatigue (4% v 1%), pneumonitis (3% v 0%), and hyperglycemia
(5% v , 1%) and Rugo et al54,55 reported a higher discontinuation
rate because of adverse events in those receiving everolimus com-
pared with placebo in combination with exemestane (9% v 3%).
Endocrine therapy with or without CDK 4/6 inhibitors. Turner
et al17 reported signiﬁcantly higher grade 3 to 4 neutropenia
(62% v 0.6%), without an increase in febrile neutropenia, in
patients receiving palbociclib in combinationwith letrozole compared
with those receiving placebo and letrozole.
Endocrine therapy plus a pan-PI3K inhibitor. Baselga et al52
reported signiﬁcantly higher grade 3 to 4 rash (7.9% v 0%), liver
enzyme elevation (AST, 18% v 2.8%; ALT, 25.5% v 1.1%), hy-
perglycemia (15.4% v 0.2%), anxiety (5.4% v 0.9%), and de-
pression (4.4% v 0.4%) in patients receiving buparlisib in
combination with fulvestrant compared with those receiving
placebo and fulvestrant.
RECOMMENDATIONS
CLINICAL QUESTION 1
Is there an optimal (deﬁned throughout this guideline as
treatments with demonstrated beneﬁts in both treatment-related
and quality-of-life outcomes) ﬁrst-line endocrine therapy regimen
for HR-positive metastatic breast cancer?
1.1 For postmenopausal women:What are the optimal sequence
and duration?
1.2 Should hormone therapy be administered in combination
with other hormonal agents or chemotherapy?
1.3 For premenopausal women: What is the optimal timing of
ovarian suppression or ablation? Should all patients have
their ovaries suppressed? What is the best partner hormonal
agent in this setting?
1.4 Are there demonstrated differences between pre- and
postmenopausal patients?
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Question 1.1
For postmenopausal women: What are the optimal sequence
and duration?
Recommendation 1.1
Postmenopausal women with HR-positive MBC should be
offered AIs as ﬁrst-line endocrine therapy (Fig 1) (Type: evidence
based, beneﬁts outweigh harms; Evidence quality: high; Strength of
recommendation: strong).
Qualifying statements. Treatment decisions must take into
account exposure to adjuvant endocrine therapy. There is no
survival difference between patients treated with AIs or tamoxifen
in randomized controlled trials. Stronger evidence exists for
nonsteroidal AIs (eg, letrozole or anastrozole) compared with
steroidal AIs (eg, exemestane) in the ﬁrst-line setting. This rec-
ommendation includes patients without prior exposure to AIs or
those experiencing relapse. 12 months after completing adjuvant
AI therapy. There is insufﬁcient evidence to recommend fulves-
trant in the ﬁrst-line setting (deﬁned as 500 mg every 2 weeks for
three doses followed by 500 mg administered once per month [ie,
optimal dose and schedule of fulvestrant]); a prospective study is
ongoing. Emerging data on targeted agents must be taken into
consideration.
Literature review and analysis. Previous studies compared AIs
with tamoxifen as ﬁrst-line therapy for metastatic disease.32,37,57-59
AIs generally resulted in improved PFS or TTP without having an
impact on OS. A meta-analysis30 concluded that tamoxifen and
toremifene were similar in efﬁcacy, with some differences in re-
ported adverse events.
One small phase II trial and one placebo-controlled phase III
trial22 compared single-agent anastrozole with exemestane in the
ﬁrst-line setting. Although TTP was numerically longer with
anastrozole in the phase II trial, this difference was not signiﬁcant.
The phase III trial demonstrated similar TTP, overall response, and
OS, and both agents were well tolerated.
The phase II FIRST trial14 compared anastrozole with ful-
vestrant at a 250-mg dose followed by 500 mg (500 mg on days 0,
14, and 28, then 500 mg every 28 days) in the ﬁrst-line setting.14
The primary end point of this trial was CBR, which was similar
between the two arms. With longer follow-up, fulvestrant was
associated with a signiﬁcant improvement in TTP, without an
increase in toxicity. On the basis of these data, survival was added as
a secondary end point by amendment, although some patients
were lost to follow-up and were censored at the time of last contact.
OS was improved in patients treated with fulvestrant15 (Table 3);
the phase III FALCON trial (Data Supplement 7; ClinicalTrials.gov
identiﬁer NCT01602380) is comparing these treatments.
Two trials compared the combination of fulvestrant and the
nonsteroidal AI anastrozole with anastrozole alone in the ﬁrst-line
metastatic setting, with opposing results. The FACT (Fulvestrant
and Anastrozole Combination Therapy) trial13 found no impact on
Table 4. QoL
Source
Intervention or
Comparison
Treatment
Line
No. of Patients
Evaluated QoL Instrument
Summary
Score
Subscale
Summary Score
Single-agent v single-agent
hormone therapies
Phase III
Di Leo21,53; CONFIRM Fulvestrant 250 mg Second 374 FACT-B NR NR
Fulvestrant 500 mg 362 TOI NR NR
P NS
Chia20; EFECT Fulvestrant Second NR FACT-ES NR NR
Exemestane NR TOI NR NR
P NS
Endocrine therapy 6
mTOR inhibitors
Phase III
Yardley50; BOLERO-2 Exemestane Second 239 EORTCQLQ-C30, QLQ-BR23 NR Emotional and/or social
TTD,
13.8 → 9.5;
24.3
Everolimus 1
exemestane
485 NR 13.9 → 11.5; 22.4
P NS
Endocrine therapy 6 CDK
4/6 inhibition
Phase III
Turner17; PALOMA-3 Fulvestrant 1 placebo $ Second 171 EQ-5D, EORTC QLQ-C30 24.0* Emotional, 21.9†
Fulvestrant 1
palbociclib
347 EORTC QLQ-BR23 20.9 2.7
P .03 .002
Abbreviations: CDK, cyclin-dependent kinase; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer 30;
EORTC QLQ-BR23, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer 23; EQ-5D, EuroQol Group Five-
Dimension Self-Report Questionnaire; FACT-B, Functional Assessment of Cancer Therapy–Breast; FACT-ES, Functional Assessment of Cancer Therapy–Endocrine
Symptoms; mTOR, mammalian target of rapamycin; NR, not reported; NS, not signiﬁcant; QoL, quality of life; TOI, trial outcome index; TTD, time to deﬁnitive
deterioration.
*Mean overall change from baseline in QLQ-C30 score.
†Mean change from baseline (score, 0 to 100).
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TTP or OS, whereas SWOG 022612 found a signiﬁcant improve-
ment in PFS, with a borderline 6.4-month improvement in OS.
Major differences in the trial populations are thought to explain
this difference; almost half of the patients in the SWOG trial had
de novo metastatic disease, with no prior exposure to adjuvant
hormone therapy (ie, tamoxifen). In contrast,. 60% of patients in
the FACT trial had received prior endocrine therapy, and , 20%
were diagnosed as having de novo metastases. There were no
signiﬁcant toxicity differences between single-agent and com-
bination therapy.
A recent study evaluated the addition of the CDK 4/6 inhibitor
palbociclib to the nonsteroidal AI letrozole and demonstrated
a signiﬁcant improvement in PFS, without an improvement in OS.7
These data led to accelerated FDA approval of this combination in
the ﬁrst-line setting, pending results from an ongoing phase III trial
in the same setting.
There were no recent trials comparing chemotherapy with
chemotherapy plus concurrent hormone therapy in the treatment of
HR-positive metastatic disease. ECOG 318610 randomly assigned 231
women to receive chemotherapy or chemotherapy with tamoxifen and
ﬂuoxymesterone. This trial included patients with both ER-positive
and ER-unknown disease, as well as both post- and premenopausal
women. Time to treatment failure (TTF) was similar between the two
treatment groups, although in the subset of women with ER-positive
disease, TTF was longer in patients receiving combination therapy.
There was no difference inOS. Of note, all recent studies have included
only postmenopausal women (regardless of age).
Clinical interpretation. In postmenopausal women, AIs may
provide better disease control compared with tamoxifen in the ﬁrst-
line setting, without a beneﬁt in OS. Available data suggest that either
nonsteroidal or steroidal AIs can be used without differential efﬁcacy.
Toremifene is a reasonable alternative to tamoxifen, with a slightly
different toxicity proﬁle and substantially higher cost. Toremifene can
be used in conjunction with inhibitors of CYP2D6 and may be an
option in some women receiving such inhibitors (eg, ﬂuoxetine).
Although results from the FIRST trial are encouraging, de-
ﬁnitive data from an ongoing phase III trial will be required
(Data Supplement 7; ClinicalTrials.gov identiﬁer NCT01602380) to
understand the potential differences in efﬁcacy between fulvestrant
(at the currently approved dose) and AIs.
It is reasonable to combine palbociclib with an AI as ﬁrst-line
therapy, because this combination prolongs PFS. Phase III data
are expected in 2016. Toxicity, the need for monthly blood counts,
and drug access must be taken into account in making this
decision.
Treatment should be administered until disease progression is
documented by imaging, examination, or symptoms. Care should
be taken in the interpretation of bone imaging and serum tumor
Third line or greater
Prior adjuvant endocrine therapy
No prior adjuvant
endocrine therapy
  Al (nonsteroidal)
  Fulvestrant
  Al + palbociclib
  Al (nonsteroidal)
  Al + fulvestrant
  Al + palbociclib
  Tamoxifen
Prior treatment with tamoxifen Prior treatment with an Al
First
line
  Al, nonsteroidal
   preferred
  Al + fulvestrant
  Al + palbociclib
Second
line
  Fulvestrant ± 
   palbociclib
  Al + everolimus
  Al (steroidal)
  Tamoxifen
Early relapse
(≤ 12 months
since adjuvant
therapy)
Late relapse
(> 12 months
since adjuvant
therapy)
Early relapse
(≤ 12 months
since adjuvant
therapy)
Late relapse
(> 12 months
since adjuvant
therapy)
  Al (nonsteroidal)
  Fulvestrant
  Al + palbociclib
  Tamoxifen
  Fulvestrant ± 
   palbociclib
  Al + everolimus
  Al (steroidal)
  Tamoxifen
Depending on prior
 therapy:
  Fulvestrant ±
   palbociclib
  Al + everolimus
  Al (steroidal)
  Tamoxifen (late
    relapse)
  Fulvestrant ±
  palbociclib
  Al + everolimus
  Al (steroidal)
  Tamoxifen
Sequential therapy based on 
 prior exposure and response
 to hormone therapy
  Estradiol (2 mg three 
    times per day)
  Megestrol acetate
  Fluoxymesterone
  Reintroduction of
    prior therapy
Fig 1. Hormone therapy forpostmenopausal
women with hormone receptor–positive
metastatic breast cancer by line of therapy
and adjuvant treatment. NOTE. Use of pal-
bociclib should be reserved for patients
without prior exposure to cyclin-dependent
kinase 4/6 inhibitors. Fulvestrant should be
administered at 500 mg every 2 weeks for
three cycles, then once per month as an
intramuscular injection. Withdrawal of ta-
moxifen or progestinswas reported to result
in short-term disease responses in older lit-
erature. Steroidal indicates exemestane; non-
steroidal indicates anastrozole or letrozole. AI,
aromatase inhibitor.
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markers, because results may be misleading. Withdrawal responses
have been observed in patients after long periods of disease control
with hormone therapy.
Question 1.2
Should hormone therapy be administered in combination
with other hormonal agents or chemotherapy?
Recommendation 1.2
Combination hormone therapy with fulvestrant, with a loading
dose followed by 500 mg every 28 days, plus a nonsteroidal AI may
be offered to patients with MBC without prior exposure to adjuvant
endocrine therapy (Fig 1) (Type: evidence based, beneﬁts outweigh
harms; Evidence quality: intermediate; Strength of recommenda-
tion: moderate).
Qualifying statements. The recommendation for combination
therapy in patients treated in the ﬁrst-line setting without prior
exposure to adjuvant hormone therapy (tamoxifen) is on the basis
of positive survival results from the SWOG 0226 randomized phase
III trial; the greatest beneﬁt in PFS was observed in an unplanned
subset analysis of approximately 400 patients who had no prior
exposure to hormone therapy. A similar study showed no beneﬁt
from combination therapy, but important differences in study
design and patient populations existed between the two trials. The
use of fulvestrant 500 mg with a loading schedule in combination
with anastrozole is being studied in a phase III neoadjuvant trial.60
There are no ongoing trials studying high-dose fulvestrant in
combination with AIs in MBC.
Literature review and analysis. Conﬂicting data exist regarding
the value of ﬁrst-line combined endocrine therapy with low-dose
fulvestrant and a nonsteroidal AI compared with an AI alone.
These data are further complicated by the use of low-dose ful-
vestrant in these trials, because the 500-mg dose was shown to be
superior to 250 mg in the trial and is now the approved dose.
Beneﬁt from the combination of low-dose fulvestrant and
a nonsteroidal AI seems to be limited to patients without prior
exposure to hormone therapy for breast cancer or with de novo
HR-positive metastatic disease. Ongoing trials are evaluating the
combination of high-dose fulvestrant with a nonsteroidal AI.
Older studies compared the combination of chemotherapy
and hormone therapy with chemotherapy. A cooperative group
trial randomly assigned 231 patients with MBC to cyclophos-
phamide, doxorubicin, and ﬂuorouracil with or without tamoxifen
and ﬂuoxymesterone from 1988 to 1992.10 The response rate was
similar between the two arms. TTF was longer in patients with HR-
positive disease receiving chemotherapy plus hormone therapy, but
there was no difference in OS.
Clinical interpretation. On the basis of the SWOG 0226 data,
the combination of low-dose fulvestrant and an AI could be
considered in the unique population of patients with HR-positive
MBC without prior exposure to hormone therapy. This recom-
mendation will be affected by the results of ongoing trials eval-
uating fulvestrant 500 mg and combination studies with targeted
agents.
Limited efﬁcacy data do not support a compelling clinical
advantage for the use of combined chemotherapy and endocrine
therapy. Sequential therapy is preferred.
Question 1.3
For premenopausal women: What is the optimal timing of
ovarian suppression or ablation? Should all patients have their ovaries
suppressed? What is the best partner hormonal agent in this setting?
Recommendation 1.3
Premenopausal women with HR-positive MBC should be
offered ovarian suppression or ablation in combination with
hormone therapy. Ovarian suppression with either GnRH agonists
or ablation with oophorectomy seems to achieve similar results in
MBC. For most patients, clinicians should use guidelines for
postmenopausal women to guide the choice of hormone treat-
ment, although sequential therapy can also be considered. Patients
without exposure to prior hormone therapy can also be treated
with tamoxifen or ovarian suppression or ablation alone, although
combination therapy is preferred (Fig 2). Treatment should be on
the basis of the biology of the tumor and the menopausal status of
the patient, with careful attention paid to production of ovarian
estrogen (Type: evidence based, beneﬁts outweigh harms; Evidence
quality: high; Strength of recommendation: strong).
Qualifying statements. Premenopausal women without prior
exposure to hormone therapy should be treated with ovarian
suppression and tamoxifen or ovarian suppression and an AI.
Tamoxifen alone can also be considered, although available data
suggest improved outcomes when ovarian suppression is also
used.18,19 All clinically important trials of endocrine therapy for
advanced breast cancer in the past decade have included only post-
menopausal women or, less commonly, premenopausal women
rendered postmenopausal at the time of study entry. There are no
clinically important data in the current era for endocrine therapy for
advanced breast cancer in women who remain premenopausal. For
that reason, and because of data supporting ovarian suppression as
initial therapy for premenopausal women with ER-positive MBC, the
panel uniformly recommends that premenopausal women start
ovarian suppression. Thereafter, treatment of premenopausal
women parallels that of postmenopausal women (Figs 1 and 2).
A discussion between the oncologist and the patient regarding
risks and beneﬁts is critical. Premenopausal women who develop
metastatic disease while receiving adjuvant tamoxifen or within
12 months of treatment should be treated with ovarian suppression
and an AI. Ovarian suppression should be continued during sub-
sequent hormone therapies. Patient choice and clear discussion of
options and treatment goals are critical.
Although historic data suggest comparable results with GnRH
agonist therapy and surgical oophorectomy,61 caution should be
exercised when GnRH agonists are used, because suppression of
ovarian production of estrogen may be incomplete, particularly
when combined with AIs or when administered once every
3 months (this schedule is not recommended). Estradiol levels
performed with a high-sensitivity assay should be monitored in
premenopausal women treated with GnRH agonists and AIs.
Providers should recognize and acknowledge special issues
faced by premenopausal women with MBC, including loss of fer-
tility. Although required systemic treatment will preclude pregnancy
for most patients, options such as cryopreservation of embryos or
oocytes should be discussed, with a careful evaluation of the lim-
itations associated with metastatic disease.
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Literature review and analysis. There were no recent studies
addressing optimal timing of ovarian suppression or the most
effective hormone combinations in premenopausal women with
MBC. Previous data demonstrated efﬁcacy with ovarian ablation,
similar to that seen with tamoxifen.62 Several small randomized
trials and a meta-analysis conﬁrmed the efﬁcacy of tamoxifen in
premenopausal women with HR-positive MBC.63
Ovarian suppression with GnRH agonists and ovarian abla-
tion resulted in similar outcomes in a phase III trial,61 leading to
widespread use of these agents as treatment of metastatic disease.
One study compared a GnRH agonist and tamoxifen with the
GnRH agonist or tamoxifen alone as treatment for premenopausal
women with MBC,18 reporting improved response duration and
survival with the combination therapy compared with either ta-
moxifen or the GnRH agonist alone. A meta-analysis of four trials
demonstrated improved response, PFS, and OS in patients re-
ceiving combination therapy.19 QoL and toxicity data were not
routinely collected.
AIs are contraindicated in premenopausal women, because
the reduction in tissue estrogen can lead to increased secretion of
gonadotropins, causing compensatory rises in ovarian estrogens
and possible induction of ovulation. This issue is most relevant for
women who were premenopausal at the time of diagnosis and are
now amenorrheic as a result of chemotherapy. Three small non-
randomized trials evaluated the combination of OS and an AI and
demonstrated efﬁcacy with varying degrees of ovarian suppression.64-66
Although not included in the evidence base because of the nature of
their trial design (nonrandomized phase II), these three trials64-66
provide important data that inform the use of hormone therapy
in premenopausal women with HR-positive MBC.
Ovarian suppression is required in premenopausal women
receiving an AI. However, there are no data deﬁning the optimal
level of plasma estradiol, and tests vary widely in sensitivity,
resulting in noncomparable results. Inferential data suggesting
a relationship between poor plasma suppression of estradiol and
worse outcomes in obese women with breast cancer receiving
AIs,64-68 as well as a fundamental consideration of mechanisms of
action, suggest that adequate ovarian suppression is important for
efﬁcacy in MBC.
Clinical interpretation. Current data suggest that ovarian
suppression or ablation in combination with tamoxifen is superior
to tamoxifen alone as ﬁrst-line therapy for premenopausal women.
Tamoxifen or ovarian suppression alone can be considered in
patients who are naı¨ve to prior hormone therapy.
Ovarian suppression with GnRH agonists is an acceptable
alternative to surgical oophorectomy. The combination of
Third line or greater
Prior adjuvant endocrine therapy
No prior adjuvant
endocrine therapy
First
line
Second line
(with
continued
ovarian
suppression)
Prior treatment with tamoxifen
with or without ovarian
suppression
Prior treatment with an Al
and ovarian suppression
    Fulvestrant ± 
     palbociclib
    Al + everolimus
    Al (steroidal)
    Tamoxifen
Early relapse
(≤ 12 months
since adjuvant
therapy)
Late relapse
(> 12 months
since adjuvant
therapy)
Early relapse
(≤ 12 months
since adjuvant
therapy)
Late relapse
(> 12 months
since adjuvant
therapy)
Sequential therapy based on
 prior exposure and response
 to hormone therapy
   Estradiol (2 mg three times 
     per day)
   Megestrol acetate
   Fluoxymesterone
   Reintroduction of
     prior therapy
Depending on prior
 therapy:
   Fulvestrant ±
   palbociclib
   Al + everolimus
   Al (steroidal)
   Tamoxifen
   Al (nonsteroidal)
   Fulvestrant 
   (500 mg)
  Al + palbociclib
Ovarian 
 suppression plus:
    Al (nonsteroidal)
    Al + fulvestrant
    Al + palbociclib
    Tamoxifen
Ovarian 
 suppression plus:
Ovarian 
 suppression plus:
   Al, nonsteroidal
   preferred
   Al + fulvestrant
   Al + palbociclib
   Tamoxifen
Ovarian 
 suppression plus:
    Al (nonsteroidal)
    Fulvestrant
    Al + palbociclib
    Tamoxifen
Ovarian 
 suppression plus:
   Fulvestrant ±
   palbociclib
   Al + everolimus
   Al (steroidal)
   Tamoxifen
   Fulvestrant ±
    palbociclib
   Al + everolimus
   Al (steroidal)
   Tamoxifen (late
    relapse)
Fig 2. Hormone therapy for premenopausal
women with hormone receptor–positive met-
astatic breast cancer by line of therapy and
adjuvant treatment. NOTE. Use of palbociclib
should be reserved for patients without prior
exposure to cyclin-dependent kinase 4/6 in-
hibitors. Fulvestrant should be administered
at 500 mg every 2 weeks for three cycles,
then monthly as an intramuscular injection.
Withdrawal of tamoxifen or progestins was
reported to result in short-term disease re-
sponses in older literature. Steroidal indicates
exemestane; nonsteroidal indicates anas-
trozole or letrozole. AI, aromatase inhibitor.
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ovarian suppression with AIs can be effective in premenopausal
women. Signiﬁcant caution should be exercised, because
ovarian suppression may be incomplete, leading to ovarian
production of estrogen. Trials have not routinely measured
estradiol, follicle-stimulating hormone, or luteinizing hormone
levels to assess the extent of ovarian suppression. Because of the
possibility of incomplete ovarian suppression with GnRH ag-
onist therapy, clinicians should be alert to changing patient
symptoms that might suggest persistent ovarian function. It
may be helpful to conﬁrm ovarian suppression by measuring
estradiol level.
Providers should recognize and acknowledge speciﬁc is-
sues faced by premenopausal women with MBC, including loss
of fertility. Although required systemic treatment will preclude
pregnancy for most patients, options such as cryopreservation
of embryos or oocytes should be discussed, with a careful evaluation of
the limitations associated with metastatic disease.
Question 1.4
Are there demonstrated differences between pre- and post-
menopausal patients?
Recommendation 1.4
Treatment should take into account the biology of the tumor
and the menopausal status of the patient, with careful attention
paid to ovarian production of estrogen (Fig 2) (Type: evidence and
consensus based, beneﬁts outweigh harms; Evidence quality: in-
termediate; Strength of recommendation: moderate).
Qualifying statements. In premenopausal women undergoing
ovarian suppression with GnRH agonists in combination with AIs,
the AIs may stimulate production of ovarian estrogen. The optimal
level of estradiol is unknown; we recommend that the local lab-
oratory deﬁnition of menopausal levels of estradiol (using a high-
sensitivity assay) be used for this purpose.
CLINICAL QUESTION 2
Is there an optimal second-line or later endocrine therapy for
HR-positive MBC?
2.1 Should other treatment or disease-free interval play a role
in treatment selection?
2.2 Which hormone therapy should be offered?
2.3 What are the optimal timing, dose, and schedule of
treatment?
Question 2.1
Should other treatment or disease-free interval play a role in
treatment selection?
Recommendation 2.1
The choice of second-line hormone therapy should take into
account prior treatment exposure and response to previous en-
docrine therapy (Type: evidence based, beneﬁts outweigh harms;
Evidence quality: high; Strength of recommendation: strong).
Qualifying statements. Lack of beneﬁt with prior endocrine
therapy may be associated with poor or short response to sub-
sequent therapy; close monitoring should be considered. Because
of inferior efﬁcacy, treatment with the same hormonal agent on or
within 12 months of completing adjuvant therapy is not recom-
mended. Emerging data combining hormonal agents with targeted
therapy should be considered.
Literature review and analysis. Prior treatment and disease-
free interval clearly inﬂuence choice of treatment. Patients who
develop recurrent disease while receiving adjuvant hormone
therapy or within 1 year of completing that treatment are deﬁned as
having disease resistant to that speciﬁc therapy, but they can re-
spond to sequential hormone therapy. In general, disease that
recurs within the ﬁrst 2 years of adjuvant hormone therapy is
generally less responsive to hormone therapy. This information is
inferred from older natural history studies.
Clinical trials studying second-line hormone therapy included
patients who experienced relapse while receiving adjuvant therapy or
shortly after completing treatment. The BOLERO-2 (Breast Cancer
Trials of Oral Everolimus) and PALOMA-3 trials deﬁned these
patients as those experiencing relapse during or within 12 months
after the end of adjuvant treatment with a nonsteroidal AI.4,17
However, a clear and consistent deﬁnition of resistance to ad-
juvant hormone therapy is lacking, and there are no data to guide
the appropriate sequence of therapy in patients on the basis of type
of adjuvant treatment. Patients with a short disease-free interval
from diagnosis of early-stage disease to relapse and those who
experience distant relapse while receiving adjuvant hormone therapy
may have shorter responses to subsequent endocrine therapy.
Clinical interpretation. The choice of second-line hormone
therapy should take into account agents used in the adjuvant and
ﬁrst-line settings, as well as disease-free interval, response to prior
hormone therapy, organ function, and extent of disease (Fig 1).
Both exemestane and fulvestrant are reasonable options on the
basis of current data.20,21,31,36 Tamoxifen should also be considered
in patients with hormone-responsive disease.
Hormone therapy should be considered after chemotherapy
as well. Hormone therapy can be used as primary treatment or
maintenance therapy after response or reintroduced after pro-
gression with chemotherapy. Sequential hormone therapy should
be used as long as the patient seems to be beneﬁtting from hor-
mone treatment and does not have evidence of immediately life-
threatening disease or rapid progression of visceral disease while
receiving adjuvant hormone therapy.
Clinicians should consider using exemestane combined with
the mTOR inhibitor everolimus, on the basis of the results of the
BOLERO-2 trial,4 or fulvestrant combinedwith the CDK 4/6 inhibitor
palbociclib, on the basis of the results of the PALOMA-3 trial.17 In
general, if a tumor has progressed with a speciﬁc agent, other agents in
that class will not be effective. Examples include letrozole or anas-
trozole and tamoxifen or toremifene.
Question 2.2
Which hormone therapy should be offered?
Recommendation 2.2
Sequential hormone therapy should be offered to patients
with endocrine-responsive disease. Options are shown in Figure 1
(Type: evidence based, beneﬁts outweigh harms; Evidence quality:
high; Strength of recommendation: strong).
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Qualifying statements. After progression with a nonsteroidal
AI, several options exist, including the combination of exemestane and
everolimus, the combination of fulvestrant and palbociclib, or single-
agent exemestane or fulvestrant with a loading dose followed by
500 mg administered every 28 days. There was more toxicity
associated with the combination of exemestane and everolimus
compared with single-agent endocrine options; exemestane plus
everolimus resulted in an improvement in PFS without im-
provement in OS compared with exemestane alone (Figs 1 and 2).
There was also more toxicity associated with the combination of
fulvestrant and palbociclib compared with single-agent options;
fulvestrant plus palbociclib resulted in an improvement in
PFS compared with fulvestrant alone; OS data are immature at
this time (Figs 1 and 2). Randomized trials have demonstrated
similar outcomes when comparing exemestane with fulvestrant
at the 250-mg dose, with or without a loading dose.
Sequential hormone therapy should be used as long as the
patient seems to be beneﬁtting from hormone treatment and does
not show evidence of rapid progression with organ dysfunction.
New hormonal agents should not be added to existing therapy at
disease progression.
Literature review and analysis. Initial studies of third-
generation AIs compared these agents with megestrol acetate in
the second-line setting. AIs were superior to megestrol acetate,
with reduced toxicity.31,69
Several phase II trials compared low-dose fulvestrant (250 mg
every 28 days) with anastrozole in the second-line setting and found
no difference in PFS or OS, conﬁrming older studies. The phase III
EFECT study20 directly compared exemestane with fulvestrant, with
a loading dose followed by low dose (500mg on day 0, 250mg on days
14 and 28, then 250 mg every 28 days). PFS was equivalent between
the two arms, and both treatments were well tolerated.
Recent studies comparing hormonal agents for MBC have
focused on increasing dose and exposure to the selective ER
downregulator fulvestrant in an attempt to both achieve steady-
state levels earlier and increase plasma levels of the active agent.
Two small phase II trials compared fulvestrant with a loading dose
followed by high dose (500 mg on days 0, 14, and 28, then 500 mg
every 28 days) with fulvestrant with a loading dose followed by low
dose (500 mg on day 0, 250 mg on days 14 and 28, then 250 mg every
28 days) with low-dose fulvestrant (250mg every 28 days)24,25 and did
not observe a difference in PFS. Deﬁnitive results were available from
the phase III CONFIRM trial,36,53 which compared fulvestrant with
a loading dose followed by low dose with fulvestrant with a loading
dose followed by high dose, demonstrating only a 1-month im-
provement in PFS but a signiﬁcant 4.1-month improvement in OS,
without signiﬁcant toxicity. This study led to FDA approval of the
loading dose followed by high dose regimen.
The SoFEA trial38 added fulvestrant with a loading dose
followed by low dose (500 mg on day 0, 250 mg on days 14 and 28,
then 250 mg every 28 days) to anastrozole in women experiencing
disease progression with anastrozole and compared the combi-
nation with fulvestrant alone plus placebo or with exemestane.
There was no difference in PFS when comparing fulvestrant with
exemestane or the combination.
Estrogens (estradiol) and progestins (megestrol acetate) have
demonstrated efﬁcacy after progression with AIs and tamoxifen.70,71
Older data suggest that withdrawal of tamoxifen or progestins
may result in disease response in patients with hormone-responsive
MBC.72 The value of this approachwith current treatment options is
unknown.
Clinical interpretation. On the basis of current data, the
nonsteroidal AI exemestane and the selective ER downregulator
fulvestrant were equally effective in the second-line setting. Ful-
vestrant should be administered with a loading dose followed by
500mg intramuscularly eachmonth. This dose resulted in superior
survival compared with the 250-mg dose.
The addition of a new hormonal agent to an existing drug that is
no longer suppressing cancer growth is not recommended. The in-
active agent should be discontinued when there is clear evidence of
cancer progression. Additional hormone options for later-line therapy
include reintroduction of prior endocrine agents and consideration of
progestational agents (eg,megestrol acetate) or estrogens (eg, estradiol).
Patients who experience long periods of tumor control with hormone
therapy may consider withdrawal of endocrine treatment, because
continuous therapy is not always required.
Question 2.3
What are the optimal timing, dose, schedule, and duration of
treatment?
Recommendation 2.3
Fulvestrant should be administered using the 500-mg dose
and with a loading schedule (Type: evidence based, beneﬁts
outweigh harms; Evidence quality: high; Strength of recommen-
dation: strong).
Qualifying statement. These are the most effective therapeutic
dose and schedule for fulvestrant.
Literature review and analysis. The CONFIRM trial demon-
strated improved OS with a fulvestrant loading dose followed by
high dose (500 mg on days 0, 14, and 18, followed by 500 mg every
28 days) compared with a fulvestrant loading dose followed by low
dose (500 mg on day 0, 250 mg on days 14 and 28, then 250 mg every
28 days).21,36,53 Estradiol at a dose of 2 mg three times per day was as
effective as and better tolerated than a higher dose.71 Use of tumor
markers or circulating tumor cells to inform change of treatment did
not demonstrate improved survival compared with clinical symp-
toms, radiographic studies, or physical examination.73
Clinical interpretation. A fulvestrant loading dose followed by
high dose is the preferred dose and schedule for fulvestrant ad-
ministration. Estradiol should be used at a dose of 2 mg three times
per day. Hormone therapy should be continued until there is clear
evidence of disease progression on the basis of clinical symptoms,
radiographic studies, or physical examination.
CLINICAL QUESTION 3
How or should endocrine therapies be used in combination or
sequence with:
3.1 mTOR inhibitors (everolimus)?
3.2 CDK 4/6 inhibitors (palbociclib)?
Question 3.1
How or should endocrine therapies be used in combination or
sequence with mTOR inhibitors?
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Recommendation 3.1
Exemestane and everolimus may be offered to postmenopausal
women with HR-positive MBC who experience progression during
treatment with nonsteroidal AIs, either before or after treatment with
fulvestrant, because PFS but not OS was improved compared with
exemestane alone. Other options are shown in Figures 1 and 2. This
combination should not be offered as ﬁrst-line therapy for patients
who experience relapse . 12 months from prior nonsteroidal AI
therapy or for those who are naı¨ve to hormone therapy (Type:
evidence based, beneﬁts outweigh harms; Evidence quality: high;
Strength of recommendation: strong).
Qualifying statements. Hormonal therapy should be changed
when everolimus is initiated. Limited data support improved
clinical beneﬁt from tamoxifen and everolimus in patients with
prior exposure to nonsteroidal AIs. The combination of everolimus
and a nonsteroidal AI could be considered for patients with prior
progression with exemestane, using the general principles of se-
quential hormone therapy.
Care should be taken in patients with existing hyperglycemia,
and patients should be educated about the risks of therapy, in-
cluding stomatitis and interstitial pneumonitis. Treatment should
be individualized, with dose reductions and/or interruptions as
indicated.
Literature review and analysis. Two recent randomized trials
reported data on the efﬁcacy of the mTOR inhibitor everolimus in
combination with hormone therapy.4,43 Both studies treated pa-
tients with previous exposure to the nonsteroidal inhibitor anastrozole
or letrozole, with a strict deﬁnition of resistance used in the phase III
trial for eligibility.
The phase II open-label TAMRAD trial43 compared tamoxifen
with tamoxifen plus everolimus. The primary end point, CBR, was
superior in the combination arm. Exploratory analysis of PFS and
OS also suggested improved outcomes with everolimus. Toxicity
was increased in the combination arm.
BOLERO-24 was a phase III double-blind randomized trial
comparing exemestane plus everolimus with exemestane plus
placebo, using a two-to-one randomization scheme. PFS and CBR
were signiﬁcantly improved in the combination arm, leading to
FDA approval of the combination as second-line therapy for HR-
positive MBC. There was no statistically signiﬁcant improvement
in OS between the two arms, although there was a numeric dif-
ference of 4.4 months.
Toxicity was increased with the addition of everolimus to
hormone therapy.54,55,74 Signiﬁcant toxicities included stomatitis,
fatigue, interstitial pneumonitis (a class effect from rapamycin
analogs), and hyperglycemia, among others; more patients dis-
continued everolimus and exemestane compared with placebo
and exemestane because of adverse events. Toxicity was con-
trolled in a majority of patients with dose reductions and
interruptions.
The mTOR inhibitor temsirolimus was studied in the ﬁrst-
line setting in the HORIZON trial.44 Patients were randomly
assigned to intermittent dosing of temsirolimus plus letrozole or
letrozole plus placebo. The trial was closed early because of futility,
with no difference in PFS between the two arms. This ﬁnding has
been hypothesized to be a result of inadequate dosing of
temsirolimus and possibly a less heavily pretreated, AI-naı¨ve
population or lack of efﬁcacy.
Clinical interpretation. The combination of exemestane and
everolimus should be considered for postmenopausal women with
HR-positive MBC who experience progression during or shortly
after treatment with nonsteroidal AIs, because the combination
resulted in an almost 5-month improvement in PFS compared with
exemestane alone. Treatment must take into account the increased
toxicity seen with this combination, and careful monitoring with
appropriate dose reductions and interruptions is recommended.
Question 3.2
How or should endocrine therapies be used in combination or
sequence with CDK 4/6 inhibitors?
Recommendation 3.2
A nonsteroidal AI and palbociclib may be offered to post-
menopausal women with treatment-naı¨ve HR-positive MBC; PFS
but not OS was improved compared with the nonsteroidal AI
letrozole alone. Other options are shown in Figures 1 and 2. The
accelerated approval of palbociclib is dependent on results of an
ongoing phase III trial in the same setting (Data Supplement 8;
PALOMA-2 trial). Results from the PALOMA-2 trial will be pre-
sented at the ASCO 2016 Annual Meeting. A press release74a
conﬁrms that the trial met its primary end point. Letrozole plus
palbociclib improved PFS compared with letrozole alone as ﬁrst-
line therapy for HR-positive metastatic breast cancer in post-
menopausal women. Survival data are not yet available.
Palbociclib may also be offered in combination with fulves-
trant in patients exposed to prior hormone therapy and up to one
line of chemotherapy, on the basis of data from the phase III
PALOMA-3 trial. PFS was improved compared with fulvestrant
alone; OS data are immature (Type: evidence based, beneﬁts
outweigh harms; Evidence quality: moderate; Strength of rec-
ommendation: intermediate).
Qualifying statements. Palbociclib should be administered
once per day for 21 days every 28 days. The primary toxicity is
neutropenia; blood counts should be monitored on day 14 of the
ﬁrst two cycles and at the start of each 28-day cycle, with neu-
tropenia managed with dose delays and reductions.
Approval is for letrozole and palbociclib; any AI could be
substituted, depending on individual tolerance, although no data
exist at present. On the basis of current data, palbociclib can be
used in the ﬁrst-line setting in patients whose disease retains
sensitivity to AIs or in the later-line setting in combination with
fulvestrant.
Literature review and analysis. CDK 4/6 inhibitors were
shown to be active in HR-positive and HER2-positive cell lines,7
leading to a randomized phase II trial comparing letrozole with
letrozole plus the CDK 4/6 inhibitor palbociclib as ﬁrst-line
treatment of HR-positive MBC.7 The addition of palbociclib
doubled PFS, without having an impact on OS; treatment was
well tolerated, with the primary toxicity being uncomplicated
neutropenia. Palbociclib was administered by mouth for 21 days
every 28 days. A similar trial design was used in the randomized
phase III PALOMA-2 trial; data are expected in 2016 (Data
Supplement 8).
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The PALOMA-3 trial randomly assigned patients with prior
exposure to AIs (including premenopausal women undergoing
ovarian suppression) to palbociclib or placebo in combinationwith
fulvestrant and demonstrated more than a doubling in PFS with
the addition of palbociclib.17 Survival analysis is immature.
Toxicities included a signiﬁcant and marked increase in grade 3 to
4 neutropenia.
Two other CDK 4/6 inhibitors (ribociclib and abemaciclib)
are being tested in phase II and III trials in combination with
hormonal agents. Ribociclib is being administered for 21 days
every 28 days and is also associated with neutropenia. Abemaciclib
is being administered continuously; diarrhea is occurring more
frequently than neutropenia.75
Clinical interpretation. Palbociclib in combination with letrozole
received accelerated FDA approval as ﬁrst-line therapy for HR-positive
MBC, with ﬁnal approval pending the results of the phase III trial of
the same design. This treatment can now be considered as a treatment
option for patients in this setting.
Although there are no data supporting other AIs in combination
with palbociclib, it is reasonable to consider other nonsteroidal or
steroidal AIs in the ﬁrst-line setting on the basis of individual tol-
erance. On the basis of the data from PALOMA-3, it is also reasonable
to consider the combination of fulvestrant and palbociclib in patients
experiencing progressionwith AIs andwith no prior exposure to CDK
inhibitors. Blood counts must be monitored before the start of each
new cycle as well as on day 14 of the ﬁrst two cycles, with dose delays
and reductions to manage neutropenia. Phase III data on ribociclib
and abemaciclib, as well as data on palbociclib in the ﬁrst-line setting,
will be available in the near future.
CLINICAL QUESTION 4
Does estrogen or progesterone expression (high v low expres-
sion) affect hormone therapy considerations and modify recom-
mendations for hormone therapy—either the recommended agents
or dosing details—among pre-, peri-, and postmenopausal women?
Recommendation 4
Hormone therapy should be offered to patients whose tumors
express any level of ER and/or progesterone receptor (PR) (Type:
evidence and consensus based, beneﬁts outweigh harms; Evidence
quality: high; Strength of recommendation: strong).
Qualifying statements. Although in general higher levels of ER
and PR expression suggest greater likelihood of beneﬁt from en-
docrine therapy for metastatic disease, there are no speciﬁc
thresholds beyond positivity for recommending treatment. Rela-
tive expression levels vary signiﬁcantly depending on technique
and possibly tumor location. Testing for receptors should be
performed on metastatic tumor tissue to conﬁrm HR expression
and HER2 status whenever feasible and clinically indicated, be-
cause data suggest that there is potential for change in receptor
status from early- to late-stage tumors.
Literature review and analysis. There are no current data to
inform this question.76-78
Clinical interpretation. At the present time, given the ap-
propriate clinical situation, hormone therapy should be considered
for patients whose tumors express ER and/or PR. Although in
general higher levels of ER and PR expression suggest greater
likelihood of beneﬁt from endocrine therapy for metastatic disease,
there are no speciﬁc thresholds beyond positivity for recom-
mending treatment. Relative expression levels vary signiﬁcantly
depending on technique and possibly tumor location. Testing for
receptors should be performed routinely on metastatic tumor
tissue to conﬁrm HR expression, because a number of data sets
have demonstrated discordance between receptor status from
early- to late-stage disease. Testing should include not only ER and
PR but also HER2. Please refer to the ASCO recommendations for
Human Epidermal Growth Factor Receptor 2 Testing in Breast
Cancer Clinical Practice Guideline Update78a for guidance on
HER2 testing. Theremay be special settings in which a biopsy is not
feasible; in such settings, a biopsy should be considered in the
future if disease status or location changes. Caution should be used
in interpreting receptor results obtained from bone biopsies be-
cause processing may affect results.
CLINICAL QUESTION 5
How does adjuvant treatment affect recommendations for
treatment in the metastatic or advanced setting?
Recommendation 5
Treatment recommendations should be offered on the basis of
type of adjuvant treatment, disease-free interval, and extent of
disease at the time of recurrence (Figs 1 and 2). A speciﬁc hormonal
agent may be used again if recurrence occurs . 12 months from
last treatment (Type: evidence and consensus based, beneﬁts
outweigh harms; Evidence quality: high; Strength of recommen-
dation: strong).
Qualifying statement. Recurrence after short exposure to adjuvant
hormone therapy suggests relative hormone resistance. Recurrence on
or within 12 months of last exposure to a speciﬁc hormonal agent is
evidence for resistance to that agent; an alternate hormone therapy
should be considered using the sequential treatment approach.
Literature review and analysis. Adjuvant hormone therapy
is almost universally prescribed for patients with early-stage,
HR-positive breast cancer, and current data suggest that longer-
duration therapy will result in improved disease-free survival. A
majority of postmenopausal womenwill receive at least 5 years of an
AI. Premenopausal women have usually been treated with tamoxifen
with or without ovarian suppression, although AIs combined with
ovarian suppression may be increasingly used on the basis of recent
data. The type of hormone therapy administered and the time from
last treatment to recurrence are critical parameters in determining
treatment in the metastatic setting. Clinical trials have considered
relapse during or within 12 months of adjuvant hormone therapy as
evidence for resistance to that therapy. In this situation, recom-
mendations for second-line hormone therapy should be followed. For
patients whose disease is resistant to adjuvant tamoxifen, nonsteroidal
AIs should be considered. Duration of adjuvant hormone therapy
before the diagnosis of recurrence is also important. Chemo-
therapy should be considered for patients with rapid recurrence
of visceral dominant or life-threatening disease within 1 to 2 years
of starting adjuvant hormone therapy, because this is evidence of
resistance to hormone therapy.
Clinical interpretation. Recommendations are on the basis of
prior treatment, disease-free interval, and extent of disease at the
time of recurrence (Table 2).
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CLINICAL QUESTION 6
In which patients or settings is hormone therapy recom-
mended over chemotherapy?
6.1 Is there a role for combined cytotoxic and endocrine therapies?
6.2 What is the optimal duration of treatment with hormone
therapy?
Recommendation 6
Endocrine therapy should be recommended as initial
treatment for patients with HR-positive MBC, except for patients
with immediately life-threatening disease or for those who ex-
perience rapid visceral recurrence during adjuvant endocrine therapy
(Type: evidence based, beneﬁts outweigh harms; Evidence quality:
intermediate; Strength of recommendation: strong).
Qualifying statement. Other than in the setting of immedi-
ately life-threatening disease, there is no evidence that starting with
chemotherapy improves any outcome measure, including OS,
toxicity, and QoL.
Literature review and analysis. A Cochrane analysis evaluated
randomized trials comparing chemotherapy with endocrine
therapy in patients with MBC.8 In six randomized trials including
692 women, there was no signiﬁcant difference in OS. In a pooled
analysis of eight trials, chemotherapy was associated with an in-
crease in objective response rate, although this result was found to
be associated with signiﬁcant heterogeneity. Of seven published
trials, six found increased toxicity with chemotherapy. One trial
evaluated QoL and concluded that it was better with chemo-
therapy. The analysis concluded that endocrine therapy should be
used before chemotherapy except in patients with rapidly pro-
gressive disease.
Clinical interpretation. Endocrine therapy is the preferred
initial treatment for patients with HR-positive MBC, except for
patients with immediately life-threatening disease or for those who
experience rapid visceral recurrence during adjuvant endocrine
therapy. There is no evidence that starting with chemotherapy
improves any outcome measure, including OS, toxicity, and QoL.
Additional research in encouraged in this area, with current
treatment and diagnostic standards.
Question 6.1
Is there a role for combined cytotoxic and endocrine therapies?
Recommendation 6.1
The use of combined endocrine therapy and chemotherapy is
not recommended (Type: evidence based, beneﬁts outweigh harms;
Evidence quality: high; Strength of recommendation: strong).
Question 6.2
What is the optimal duration of treatment with hormone
therapy?
Recommendation 6.2
Treatment should be administered until there is unequivocal
evidence of disease progression as documented by imaging, clinical
examination, or disease-related symptoms. Tumor markers or
circulating tumor cells should not be used as the sole criteria for
determining progression (Type: evidence based, beneﬁts outweigh
harms; Evidence quality: high; Strength of recommendation: strong).
Qualifying statements. Assessment of progression may be
challenging because of the combination of difﬁculty in interpreting
imaging and the indolent nature of HR-positive disease in
some patients. Treatment should focus on patient outcomes and
symptoms. Tumor ﬂare reactions (increase in tumor-related
symptoms) can occur, particularly with tamoxifen and estradiol;
were observed shortly after beginning a new endocrine treatment;
and can be confused with disease progression. Treatment-related
toxicity may be a reason to change therapy. Patient outcomes were
not improved by changing therapy based solely on tumor markers
or circulating tumor cells.
CLINICAL QUESTION 7
Is there a role for additional biomarkers in the selection of
treatment for patients for HR-positive disease?
7.1 What is the role of genomic proﬁling or intrinsic subtypes in
this population?
Recommendation 7
Use of additional biomarkers is experimental and should be
reserved for selection of treatment in clinical trials. There is no
routine clinical role for genomic or expression proﬁling in the
selection of treatment for HR-positive MBC (Type: consensus
based, beneﬁts outweigh harms; Evidence quality: low; Strength of
recommendation: moderate).
Qualifying statements. There is no evidence to date demon-
strating a role for speciﬁc biomarkers other than ER, PR, and
HER2. Useful biomarkers would allow additional selection of
speciﬁc effective therapy.
Literature review and analysis. There is no evidence as yet
demonstrating a role for speciﬁc biomarkers other than ER, PR,
and HER2. Useful biomarkers would allow additional selection of
speciﬁc effective therapy.
Clinical interpretation. Use of additional biomarkers is experi-
mental and should be reserved for selection of treatment in clinical
trials. There is no routine clinical role for genomic or expression
proﬁling in the selection of treatment for HR-positive MBC.
Question 7.1
What is the role of genomic proﬁling or intrinsic subtypes in
this population?
Recommendation 7.1
Genomic or expression proﬁling should not be used to select
treatment for HR-positive MBC (Type: consensus based, beneﬁts
outweigh harms; Evidence quality: low; Strength of recommen-
dation: moderate).
Qualifying statement. Intrinsic subtypes have been associated
with prognosis but have not yet been shown to aid in the selection
of effective treatment. HR-positive tumors associated with mu-
tations in the BRCA1 and BRCA2 genes seem to have a response to
hormone therapy similar to that of sporadic cancers.
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Literature review and analysis. Intrinsic subtypes on the basis
of gene expression have been associatedwith prognosis but have not yet
been shown to aid in the selection of effective treatment.79,80 Genomic
proﬁling to identify speciﬁc mutations for potential targeting is of
increasing interest. However, there are no prospective data to dem-
onstrate that selection of speciﬁc treatments on the basis of genomic
proﬁling results in better disease outcomes. HR-positive tumors
associated with mutations in the BRCA1 and BRCA2 genes seem to
have a response to hormone therapy similar to that of sporadic cancers.
Clinical interpretation. There is no routine clinical role for
genomic or expression proﬁling in the selection of treatment for
HR-positive MBC.
CLINICAL QUESTION 8
How does HER2 positivity affect treatment of patients with
HR-positive MBC?
Recommendation 8
The addition of HER2-targeted therapy to ﬁrst-line AIs should
be offered to patients with HR-positive, HER2-positive MBC in
whom chemotherapy is not immediately indicated. The addition of
HER2-targeted therapy to ﬁrst-line AIs improved PFS, without
a demonstrated improvement in OS. HER2-targeted therapy
combined with chemotherapy resulted in improvements in OS and
is the preferred ﬁrst-line approach in most cases (Type: evidence
and consensus based, beneﬁts outweigh harms; Evidence quality:
high; Strength of recommendation: strong).
Qualifying statements. The choice of chemotherapy versus
hormone therapy should be driven by the clinical and biologic
characteristics of the disease, with hormone therapy reserved
for more indolent disease. Chemotherapy in combination with
HER2-targeted therapy is indicated in de novo and visceral dominant
disease, because this treatment offers a survival beneﬁt compared with
chemotherapy alone. Hormone therapy has also been used as
maintenance treatment after response to chemotherapy, com-
bined with ongoing HER2-targeted therapy, although there is no
evidence to support beneﬁt in this setting.
Literature review and analysis. Expression of the HER2/neu
receptor or HER2 gene ampliﬁcation has been associated with
reduced and shorter duration of response to endocrine therapy
because of cross talk with the ER and activated growth factor
receptor signaling pathways.81 Two randomized trials evaluated the
addition of HER2-targeted agents to ﬁrst-line AI therapy in MBC.
The ﬁrst study evaluated trastuzumab plus anastrozole versus
anastrozole alone in patients with HR-positive, HER2-positive
disease, and the second study evaluated letrozole plus lapatinib
versus letrozole alone in patients with HR-positive disease and also
evaluated the subset who were HER2 positive.5,6 Both trials re-
ported a signiﬁcant improvement in PFS, although the difference
was larger in the lapatinib study. Of note, PFS in both trials was short
for patients treated with an AI alone, ranging from 2.4 to 3 months.
Neither study showed a difference in OS; treatment was well tolerated.
A small randomized trial reported a large but nonsigniﬁcant difference
in TTP favoring letrozole plus trastuzumab over letrozole.41 There are
no data evaluating the efﬁcacy of tamoxifen plus trastuzumab,
although this combination could be considered in patients
experiencing disease progression with AIs who are not candidates
for chemotherapy combined with HER2-targeted therapy.
Clinical interpretation. In patients with HR-positive, HER2-
positive MBC, the addition of HER2-targeted therapy to ﬁrst-line
AIs improved PFS, without a demonstrated improvement in OS.
HER2-targeted therapy combined with chemotherapy resulted in
improvements in OS; therefore, in most cases, this is the preferred
ﬁrst-line approach.
The choice of chemotherapy versus hormone therapy should
be driven by the clinical and biologic characteristics of the disease,
with hormone therapy reserved formore indolent disease. Hormone
therapy has also been used as maintenance treatment after response
to chemotherapy, combined with ongoing HER2-targeted therapy,
although there is no evidence to support beneﬁt in this setting. For
ASCO guidance on treatment for patients with advanced HER2-
positive breast cancer, please see the Clinical Practice Guideline on
systemic therapy for patients with advanced HER2-positive breast
cancer.80a
CLINICAL QUESTION 9
What are the future directions for treatment in this patient
population?
Recommendation 9
Patients should be encouraged to consider enrolling in clinical
trials, including those receiving treatment in the ﬁrst-line setting.
Multiple clinical trials are ongoing or planned, with a focus on im-
proving response to hormone therapy in metastatic disease (Type:
evidence and consensus based, beneﬁts outweigh harms; Evidence
quality: intermediate; Strength of recommendation: moderate).
Qualifying statements. Determining biomarkers to predict
response to speciﬁc targeted agents is a critical investigative path.
Ongoing clinical trials are investigating mechanisms of resistance,
predictive biomarkers, and a series of novel agents added to hormone
therapy for MBC, with some of the most promising agents including
PI3K inhibitors, additional CDK 4/6 inhibitors, HDAC, androgen
receptor antagonists, selective ER downregulators such as fulvestrant,
and new HER2-targeted agents. In addition, biomarker studies
evaluating ERmutations and their impact on treatment outcomes
and drug selection are under way.82
Two trials have now been reported comparing the combi-
nation of a pan-PI3K inhibitor and hormone therapy. Both trials
showed no or minimal improvements in PFS and a signiﬁcant
increase in toxicity with the addition of the PI3K inhibitor.51,52
Additional trials are ongoing with alpha-speciﬁc PI3K inhibitors
(Data Supplement 8).
Although the addition of bevacizumab to ﬁrst-line endocrine
therapy modestly improved PFS in two trials, OS was not improved,
and toxicity was increased.48,49 This therapy is not recommended in
combination with hormone therapy for breast cancer.
Literature review and analysis. Preclinical research has identiﬁed
pathways important in hormone resistance. The PI3K pathway is the
most common altered pathway in HR-positive disease. It has been
challenging to identify biomarkers that predict response to speciﬁc
agents or combinations, other than ER and PR. Biomarkers identiﬁed
in clinical trials have been prognostic but not predictive.
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The phase II FERGI trial randomly assigned 168 women with
HR-positive MBC with prior exposure to an AI to receive the pan-
PI3K inhibitor pictilisib (GDC-0941) or placebo in combination
with fulvestrant.51 There was no signiﬁcant difference in PFS between
the two arms, and toxicities including rash and diarrhea resulted in
dose modiﬁcations and discontinuations. There was no difference in
efﬁcacy on the basis of PI3Kmutation status. The phase III BELLE-2
trial randomly assigned 1,147 postmenopausal women with HR-
positive MBC experiencing progression during or after an AI to
receive the pan-PI3K inhibitor buparlisib or placebo with fulves-
trant.52 PFS was improved from 5 to 6.9 months, which was statis-
tically but not clinically signiﬁcant in either the whole group or in
patients whose tumors had activated PI3K. Toxicities included grade 3
to 4 liver function abnormalities, hyperglycemia, rash, fatigue, and
depression. An exploratory analysis in a small subset found higher
response rates in those receiving buparlisib who had evidence of
PIK3CA mutations in circulating tumor DNA. On the basis of these
data, pan-PI3K inhibitors are unlikely to move forward in the clinical
setting. However, it is clear that additional studies should include
analyses of pathway activation, and evaluation of circulating tumor
DNA is a promising area for further study.
Alpha-speciﬁc PI3K inhibitors have demonstrated efﬁcacy in the
treatment of HR-positive but hormone-resistant disease without clear
association with underlying PI3K mutation status. Several ongoing
clinical trials are evaluating these agents in the MBC setting, including
the SOLAR-1 trial (alpelisib) and the SANDPIPER trial (Data Sup-
plement 8).
HDAC inhibitors can block post-translational silencing of the
ER. The HDAC inhibitor entinostat improved PFS and OS when
combined with exemestane compared with exemestane alone in
a randomized phase II trial.50 A phase III trial (ClinicalTrials.gov
identiﬁer NCT02115282) is ongoing (Data Supplement 8).
Inhibitors of the ﬁbroblast growth factor receptor have
demonstrated activity in the treatment of HR-positive MBC. Two
agents (lucitinib and dovitinib) are being actively studied in phase
II clinical trials.83
A majority of HR-positive tumors also express the androgen
receptor. Recent studies have suggested that antagonists of the an-
drogen receptor may have activity in hormone-resistant HR-positive
MBC, and additional trials are planned or ongoing.
A study of the addition of pertuzumab in combination with
trastuzumab and an AI is being compared with trastuzumab plus
an AI in an ongoing randomized trial (ClinicalTrials.gov identiﬁer
NCT01491737), with the goal of both assessing the beneﬁt of
pertuzumab and identifying patients whose HER2-positive tumors
can be treated with hormone therapy rather than chemotherapy in
the ﬁrst-line setting (Data Supplement 8).
Combinations of targeted therapies have demonstrated efﬁcacy in
preclinical studies. Several of these combinations have been or are
being testing in clinical trials, including the combination of CDK 4/6
and PI3K inhibition.84 Toxicity from combination therapy is a sig-
niﬁcant issue that limits at least some approaches. The combination of
an mTOR inhibitor and an inhibitor of IGFR did not improve out-
comes relative to themTOR inhibitor alone in one recent phase II trial.
Mutations in the ER (ESR1) have been identiﬁed as markers of
resistance and poor outcomes, although no speciﬁc therapy to
target this site has been identiﬁed to date.
Clinical interpretation. Multiple clinical trials are ongoing or
planned, with a focus on improving response to hormone therapy
in metastatic and early-stage disease. Biomarkers to predict re-
sponse to speciﬁc targeted agents is a critical investigative path.
Areas of speciﬁc interest in combination with hormone therapy
include PI3K inhibitors, HDAC inhibitors, CDK 4/6 inhibitors,
ﬁbroblast growth factor receptor inhibitors, selective ER down-
regulators, combinations of HER2-targeted therapies, and com-
binations of different targeted therapies.
Enrollment in clinical trials should be encouraged at all lines of
therapy and in all stages of treatment. Physician and patient education
about clinical trials is crucial. Future studies should strive to include
at least a population of patients with multiple chronic conditions
(MCCs) to better represent the real-world population.
DISCUSSION
Endocrine therapy is a mainstay of treatment for women with
HR-positive MBC. High-level evidence exists for use of most of
the commonly prescribed treatments, and a vast historical lit-
erature is available to guide overarching treatment principles.
Most women with HR-positive MBC will be candidates for multiple
lines of endocrine therapy and for multiple lines of chemotherapy
when their tumors are resistant to hormonal agents. It is not un-
common for patients to alternate between endocrine therapy and
chemotherapy over the course of their treatment program, on the
basis of the extent of cancer burden, the adverse effects of therapy, and
the symptoms associated with their cancer.
As shown in the algorithms (Figs 1 and 2), a variety of sequences
for endocrine therapy can be appropriate. The choice of a speciﬁc
agent or approach is inﬂuenced by menopausal status, prior adjuvant
endocrine therapy, disease-free interval, prior treatment of advanced
disease, and the adverse effect proﬁle of the treatment plan. Because
few of these treatment nodes are associated with marked survival
advantages or major differences in clinical beneﬁt, clinicians and
patients can exercise discretion in choosing appropriate treat-
ments. For postmenopausal patients, the panel prefers single-
agent AI therapy, or AI in combination with fulvestrant for select
situations, as initial therapy.
The CDK 4/6 inhibitor palbociclib may be added to ﬁrst-line
therapy with an AI. In second-line treatment for postmenopausal
women, the panel recommends either fulvestrant plus palbociclib
or exemestane plus everolimus; single-agent hormone therapy can
also be considered. The panel prefers the combination of tamoxifen or
an AI with ovarian suppression as initial therapy for premenopausal
patients. Treatment thereafter mirrors that recommended for post-
menopausal women, with ongoing ovarian suppression and use of an
AI as second-line therapy if tamoxifen was used in the ﬁrst line,
with consideration of subsequent agents, including targeted
agents, as appropriate.
Clinicians are reminded that endocrine therapy may be rein-
troduced after the initiation of chemotherapy as either maintenance
therapy or as a next step in sequential treatment. Although these
strategies are not frequently studied in clinical trials evaluating en-
docrine agents for regulatory purposes, it is an appropriate and
important consideration for clinical practice. Clinicians can offer
endocrine treatment asmaintenance therapy after a successful response
30 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Rugo et al
Downloaded from jco.ascopubs.org on June 24, 2016. For personal use only. No other uses without permission.
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
to chemotherapy (or in the case ofHR-positive, HER2-positive tumors,
after a response to chemotherapy and anti-HER2 agents, with con-
tinuation of the anti-HER2 agents) or as treatment of chemotherapy-
resistant disease. Considerations in the choice of agent when endocrine
therapy is reintroduced are similar to those outlined in this article.
Anecdotal reports have described tumor response or prolonged periods
of stable disease with reintroduction of endocrine therapy using either
new or previously administered agents.
Agents targeted to biologic pathways associated with resistance to
hormone therapy are being studied in numerous clinical trials, with
encouraging preliminary data. Phase III trials testing CDK 4/6, PI3K,
and HDAC inhibitors are ongoing or have completed accrual, with
results expected in 2015 to 2016. These new approaches, although
costly, may change our approach to the treatment of HR-positive
MBC in the near future.
EXTERNAL REVIEW
The draft clinical practice guideline was distributed to three cli-
nicians who were not members of the Expert Panel for review
(Acknowledgment [online-only]). Although the three reviewers
were in agreement with the systematic review results, the Expert
Panel’s interpretation of the evidence, and the draft recommen-
dations, comments were received concerning the lack of guidance
around rebiopsying metastatic tissue and retesting of ER and
HER2. In response, the working group added a section covering
these to the Introduction. All other comments, both substantive
and editorial, were considered by the working group, and changes
were made to address all comments as warranted.
RECOMMENDATIONS
The recommendations were developed by a multidisciplinary
group of experts using evidence from systematic reviews with
meta-analyses and randomized trials (phases II and III), along with
clinical experience. Ratings for the type of recommendation and
strength of the evidence are offered (rating deﬁnitions are provided
in the Methodology Supplement).
SPECIAL COMMENTARY
The treatment of HR-positive MBC is rapidly changing, with new
targeted therapies now available in combination with hormonal
agents. Results from a number of phase II and III trials will be
reported in the next 2 years; this is likely to further affect the
recommendations set forth in this guideline.
PATIENT AND CLINICIAN COMMUNICATION
This section is on the basis of patient and clinician experience and
selected literature but was not part of the systematic review of the
literature. Although there are differences between issues facing
patients with different types of metastatic solid tumors, clinicians
are encouraged to refer to a similar discussion in the ASCO Clinical
Practice Guideline Update on Chemotherapy for Stage IV Non–
Small-Cell Lung Cancer (2009)85 and to literature on risk com-
munication for patients with cancer.86 A patient who is newly
diagnosed with metastatic disease versus one for whom ﬁrst- or
second-line treatment or greater has failed will likely face dif-
ferent issues. Clinical teams are encouraged to discuss the
patient’s understanding of prognosis and options in creating
a treatment plan and to discuss available clinical trials at each
treatment decision point. When communicating, clinicians should
consider issues relevant to patients with MBC, including the impor-
tance of evidence-based treatment, referral to http://www.cancer.net
links, psychosocial support, and introduction of the concepts of
concurrent palliative and antitumor therapy.85,87-89
Research that focuses on discussing speciﬁc issues with pa-
tients with advanced breast cancer is still needed. Teams should be
prepared to present the information in this guideline in a format
tailored to the patient’s and/or caregiver’s learning style and to
involve the patient as appropriate in decision making. Discus-
sions with patients should include key subjects. Suggested sample
talking points are provided in Data Supplement 4.
HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent expert rec-
ommendations on the best practices in disease management to
provide the highest level of cancer care, it is important to note that
many patients have limited access to medical care. Racial and ethnic
disparities in health care contribute signiﬁcantly to this problem in
the United States. Patients with cancer who belong to racial or ethnic
minorities disproportionately suffer from comorbidities, experience
more substantial obstacles to receiving care, are more likely to be
uninsured, and are at greater risk of receiving poor-quality care than
other Americans.90-94 Many other patients lack access to care be-
cause of their geography or distance from appropriate treatment
facilities. Awareness of these disparities in access to care should be
considered in the context of this clinical practice guideline, and
health care providers should strive to deliver the highest level of
cancer care to these vulnerable populations.
MCCS
Creating evidence-based recommendations to inform treatment of
patients with additional chronic conditions, a situation in which
the patient may have two or more such conditions—referred to as
MCCs—is challenging. Patients with MCCs are a complex and
heterogeneous population, making it difﬁcult to account for all of
the possible permutations to develop speciﬁc recommendations for
care. In addition, the best available evidence for treating index
conditions, such as cancer, is often from clinical trials, the study
selection criteria of which may exclude these patients to avoid
potential interaction effects or confounding of results associated
with MCCs. As a result, the reliability of outcome data from these
studies may be limited, thereby creating constraints for expert
groups in making recommendations for care in this heterogeneous
patient population.
www.jco.org © 2016 by American Society of Clinical Oncology 31
Endocrine Therapy Guideline for Metastatic Breast Cancer
Downloaded from jco.ascopubs.org on June 24, 2016. For personal use only. No other uses without permission.
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
Because many patients for whom guideline recommendations
apply present with MCCs, any management plan needs to take into
account the complexity and uncertainty created by the presence of
MCCs and highlight the importance of shared decision making
around guideline use and implementation. Therefore, in consid-
eration of recommended care for the target index condition, cli-
nicians should review all other chronic conditions present in the
patient and take those conditions into account when formulating
the treatment and follow-up plans.
Taking these considerations into account, practice guide-
lines should provide information on how to apply the rec-
ommendations for patients with MCCs, perhaps as a qualifying
statement for recommended care. This may mean that some or
all of the recommended care options are modiﬁed or not ap-
plied, as determined by best practice in consideration of any
MCCs.
For female patients with breast cancer who are younger than
65 years of age, the 10 most common comorbid conditions are
hypertension, hyperlipidemia, depression, arthritis, anemia, di-
abetes, ischemic heart disease, chronic obstructive pulmonary
disease, chronic kidney disease, and heart failure. For female
patients with breast cancer who are older than 65 years of age, the 10
most common comorbid conditions are hypertension, hyperlipidemia,
arthritis, anemia, ischemic heart disease, diabetes, cataracts, heart
failure, depression, and chronic kidney disease. The table in Data
Supplement 5 lists details on the number of patients affected by these
comorbid conditions and supplementary information. Estimating
a patient’s survival with MCCs exclusive of MBC can be easily
done in an ofﬁce setting and may be helpful in selecting care
(http://eprognosis.ucsf.edu).
COST IMPLICATIONS
The guideline panel understands that the treatment of metastatic
cancer is complicated by the cost of treatment and that this may limit
options in some situations. The use of combination hormone
therapy, particularly with targeted agents, clearly adds both the
cost of acquiring the agents as well as the cost of managing
adverse effects. This guideline outlines the optimal treatment
approach without considering cost or availability in speciﬁc
geographic areas of the world. Recommendations are on the basis
of clinical trials, and limitations of existing data are outlined. This
information should help with decision making when the cost of
therapy limits access to speciﬁc treatments.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation across health
settings. Barriers to implementation include the need to increase
awareness of the guideline recommendations among front-line
practitioners and cancer survivors and also to provide adequate
services in the face of limited resources. The guideline Bottom Line
was designed to facilitate implementation of recommendations. This
guideline will be distributed widely throughout the ASCO Practice
Guideline Implementation Network. ASCO guidelines are posted on
the ASCO Web site and most often published in Journal of Clinical
Oncology and Journal of Oncology Practice. Treatments that control
symptoms, delay the onset of chemotherapy, and delay progression of
disease should be emphasized within the contexts of cost and toxicity.
LIMITATIONS OF THE RESEARCH AND FUTURE DIRECTIONS
ASCO believes that cancer clinical trials are vital to inform medical
decisions and improve cancer care and that all patients should have
the opportunity to participate. It is critical that appropriate PRO
measures to evaluate symptoms and adverse effects be included in
these studies. Information regarding patient perspectives about risks
and beneﬁts of novels therapies is necessary to inform patient and
physician decision making and should include perceptions about
interventions used to ameliorate toxicity. A number of questions
have not been fully explored in the current era of treatment options,
such as the comparison of chemotherapy versus hormone therapy
on the basis of biologic subsets of disease and the sequential or
combination use of ovarian suppression and hormone therapy in
premenopausal women. Future directions include understanding
the possible beneﬁts of combining the current approved dose of
fulvestrant (500 mg every 2 weeks for three cycles, then 500 mg
per month) with AIs as ﬁrst-line therapy for MBC and studying
combinations of agents targeted to biologic pathways with hormone
therapy. Ongoing trials are evaluating double-antibody therapy with
trastuzumab and pertuzumab inHER2-positive, ER-positive disease,
as well as a variety of inhibitors of CDK4/6 and PI3K. The long-term
goal of these trials is to move more effective treatment approaches to
the early-stage setting. One major goal is to identify markers or
signatures that predict response to speciﬁc therapies. To date, these
studies have only conﬁrmed prognostic markers that do not predict
beneﬁt from speciﬁc therapies. Collaboration among groups and
analyses of pathway activation are important steps toward identi-
fying predictive markers. Future studies should strive to include at
least a population of patients withMCCs to better represent the real-
world population likely to use a speciﬁc new therapy.
ADDITIONAL RESOURCES
Additional information, including Data Supplements, evidence
tables, and clinical tools and resources, can be found at http://www.
asco.org/guidelines/advancedendocrinebreast. Patient information
is available there and at http://www.cancer.net.
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